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i1 The penicillin literature is immense. It includes both contemporary and historical, hagiographical and analytical,
descriptions and interpretations of the discovery itself and of the related scientific and clinical work; biographical
and autobiographical accounts. The Wellcome Library includes 259 items catalogued with the keyword ‘penicillin’,
and can be accessed via telnet at library.wellcome.ac.uk 
2 Some useful summaries of aspects of that revolution are included in the papers from a symposium held in 1979,
The History of Antibiotics, edited by John Parascandola (American Institute of the History of Pharmacy, Madison,
WI, 1980). Another useful general account is Antibiotics in Historical Perspective, edited by David L Cowen and
Alvin B Segelman (Merck, Sharp & Dohme, 1981).
3 These were marketed under trade names such as Beecham’s Powders, Veno’s Cough Cure, Lucozade etc.
INTRODUCTION
The introduction of penicillin during the Second World War led to a revolution in both drug
development and therapeutics.1 From the 1940s to the 1960s that revolution spread from
laboratories, institutes and companies, as penicillin was succeeded by a host of antibiotics –
some, like streptomycin, addressing specific organisms immune to penicillin, others, like
tetracycline and the cephalosporins, with a broad spectrum of activity.2 In the United States
this work underpinned the enormous growth of the pharmaceutical industry. In the United
Kingdom the development of cephalosporins and semisynthetic penicillins became matters
of national pride as well as commercial and therapeutic significance. This Witness Seminar
gathered together many of those who had been a part of that revolution, and encouraged
them to reminisce and discuss and debate the events and issues they recalled.
Several important themes emerged during the course of the meeting – including details of
the scientific research in pharmaceutical company laboratories; the mechanisms whereby
the products of that research were manufactured, marketed and utilized in the clinical
encounter; the clinical successes and subsequent problems as antibiotic resistance was
increasingly recognized.
Almost as soon as the original penicillin was produced, chemists began, as they had with the
sulphonamides in the 1930s, to examine and modify the basic molecule, in an attempt to
produce products with different antibacterial spectra. Of particular importance was the
towering figure of Sir Ernst Chain, one of the Nobel Prize winners for the original penicillin
discovery, who, from laboratories in both Rome and London, advised the pharmaceutical
company, Beecham, then beginning to undertake original scientific research. Several of the
scientists from that Beecham Group took part in the seminar, providing tantalizing insights,
not only into the development of the research process itself, but also into the newness of the
research enterprise within a pharmaceutical company better known, up to that period, for
cold cures and health drinks.3 This was, of course, in the days before the Committee on the
Safety of Drugs (later Safety of Medicines) was established, and several witnesses describe the
rapidity with which new compounds could be introduced onto the market, methicillin, for
example, taking less than 18 months to transfer from laboratory discovery in 1959 to clinical
application, a procedure that would now take at least eight years to complete (see pages
31–32). The commercial implications of these new products, and strategies of the several
rival companies all competing to produce and market antibiotics, is touched on by several
participants. Important too, is the issue of patents. Part of the penicillin story, some would
ii
say the penicillin myth, is that British rights to penicillin were carelessly disregarded,
allowing American enterprise to patent what had been a British discovery. Partially as a
consequence of that experience the National Research and Development Corporation
(NRDC) was created when the Labour Government passed the Development and Inventions
Act 1948, to safeguard and commercialize patentable ideas emerging from publicly funded
scientific research. 4 An early triumph of the NRDC was their role in the development of
cephalosporins by Glaxo, and their ‘penicillin in reverse’ licensing agreements with the
American firm of Eli Lilly, here recounted by Dr Basil Bard, a former Managing Director of
the NRDC (pages 39–40).
These new wonder drugs raised enormous clinical expectations. Their astonishing impact is
recalled by several clinicians, as are the problems that arose very quickly as the phenomenon
of antibiotic resistance was recognized. Especial mention was made by several participants of
Dr Mary Barber at the Hammersmith Hospital in London, and her introduction as early as
1957 of a hospital-wide policy to reduce the use of antibiotics (pages 36–38).
These are just a selection of the issues that are covered here by our witnesses, to whom we
are grateful for the time they gave us not only in planning and holding this meeting, but also
during the editorial process, which is described below.
4 The role of the NRDC has emerged in another witness seminar ‘Technology transfer in Britain: The case of
monoclonal antibodies’, Tansey E M, Catterall P P. (eds) (1997) in Tansey E M, Catterall P P, Christie D A,
Willhoft S V, Reynolds L A. (eds) Wellcome Witnesses to Twentieth Century Medicine, vol. 1. London: The Wellcome
Trust, 1–34.
iii
5 Much of the following text is also published in the ‘Introduction’ to vol. 5 of Wellcome Witnesses to Twentieth
Century Medicine. London: The Wellcome Trust, 2000.
6 It is the interactive nature of Witness Seminars that distinguishes them from routine oral history interviews and
reminiscences, such as those published in Moberg C L, Cohn Z A. (1990) (eds) Launching the Antibiotic Era:
Personal accounts of the disco very and use of the first antibiotics, New York, NY: Rockefeller University Press, 97.
WITNESS SEMINARS: MEETINGS AND PUBLICATIONS5
In 1990 the Wellcome Trust created the History of Twentieth Century Medicine
Group to bring together clinicians, scientists, historians and others interested in
contemporary medical history. Amongst a number of other initiatives, the format of
Witness Seminars – used by the Institute of Contemporary British History to address
issues of recent political history – was adopted, to promote interaction between these
different groups, to emphasize the potentials of working jointly, and to encourage the
creation and deposit of archival sources for present and future use.
The Witness Seminar is a particularly specialized form of oral history where several
people associated with a particular set of circumstances or events are invited to meet
together to discuss, debate, and agree or disagree about their memories.6 To date, the
History of Twentieth Century Medicine Group has held over 20 such meetings, most
of which have been published, as listed in the Table below.
Subjects for such meetings are usually proposed by, or through, members of the St e e r i n g
Committee of the Gro u p, and once an appropriate topic has been agreed, suitable
p a rticipants are identified and invited. These inevitably lead to further contacts, and more
suggestions of people to invite. As the organization of the meeting pro g resses, a flexible
outline plan for the meeting is devised, usually with assistance from the meeting’s
chairman, and some participants are invited to ‘set the ball ro l l i n g’ on particular themes,
by speaking for a short period of time to initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited transcript
is immediately sent to eve ry participant. Each is asked to check their ow n
contributions and to provide brief biographical details. The editors turn the transcript
into readable text, and part i c i p a n t s’ minor corrections and comments are
incorporated into that text, while biographical and bibliographical details are added
as footnotes, as are more substantial comments and additional material provided by
participants. The final scripts are then sent to every contributor, accompanied by
copyright assignment forms. As with all our meetings, we hope that even if the precise
details of some of the technical sections are not clear to the non-specialist, the sense
and significance of the events are understandable. Our aim is for the volumes that
emerge from these meetings to inform those with a general interest in the history of
modern medicine and medical science, to provide for historians new insights, fresh
material for study, and prompt fresh themes for research, and to emphasize to the
participants that events of the recent past, of their own working lives, are of proper
and necessary concern to historians. 
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to Twentieth Century Medicine, vol. 1. London: The Wellcome Trust, 135pp.
8 P D’Arcy Hart, edited and annotated by E M Tansey. (1998) Chronic pulmonary disease in South Wales
coalmines: An eye-witness account of the MRC surveys (1937–1942). Social History of Medicine 11: 459–468.
9 Lock S P, Reynolds L A, Tansey E M. (eds) (1998) Ashes to Ashes: The history of smoking and health. London: The
Wellcome Trust, 228pp.
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Sir Christopher Booth:1 I think the History of Twentieth Century Medicine Group
has held some very intriguing meetings over the past few years, and one of the things
that interests me is that within a historical environment people feel freer to speak the
truth about life in science than they would in a scientific meeting. I can well
remember Max Perutz coming here for a meeting on haemoglobin – and Max is the
most modest and unassuming of men – but some of the things that he told us at that
meeting were something we could never have learnt any other way than through a
historical meeting at the Wellcome Trust.2 We chose the subject of post-penicillin
antibiotics because Robert Bud and his group at the Science Museum had a very
successful meeting on penicillin (two years ago) with some of the people in Oxford
and in industry who had been involved, and I think it was his suggestion that we
should have a meeting here on the post-penicillin era of antibiotics.
We thought we would try and divide this afternoon up into four sections. Between
now and tea we would like firstly to deal with streptomycin and we have some experts
in the field of tuberculosis (TB) treatment here. Secondly, we will deal with the
semisynthetic antibiotics. Then after tea the cephalosporins and finally the very
important contemporary question of resistance and immunity and bacteria.
Dr Robert Bud:3 What an intimidating responsibility to tell people who are so
distinguished in the area, about their own work. But just to set a framework for this
meeting. We could not have known, of course, when we started organizing it that it
would follow so closely upon the enormously widely reported House of Lords report
on antibiotic resistance which gives an urgent timeliness to our discussion today.4 Of
course, the penicillin story itself has been told numerous times, particularly by the
participants, one might say. There’s the famous film, made in 1944 originally, by ICI,
1 Sir Christopher Booth Kt FRCP (b. 1924) trained as a gastroenterologist and was the first Convenor of the
Wellcome Trust’s History of Twentieth Century Medicine Group, from 1990 to 1996, and Harveian Librarian at
the Royal College of Physicians from 1989 to 1997. He was Professor of Medicine, Royal Postgraduate Medical
School, Hammersmith Hospital, London, from 1966 to 1977 and Director of the Medical Research Council’s
Clinical Research Centre, Northwick Park Hospital, Harrow, from 1978 to 1988.
2 The History of Twentieth Century Group held a Summer School on the History of Haemoglobin, 14–16 July
1993, at the Wellcome Building, London. Invited speakers were Professor Larry Holmes, Dr John Edsall, 
Dr Harmke Kamminga, Dr Max Perutz, Professor Irving London, Professor V H Ingram, Professor Franklin Bunn,
Professor Sir David Weatherall, Professor Lucio Luzzatto, Professor Morris Goodman, Dr John Clegg and
Professor John West. The proceedings have not been published.
3 Dr Robert Bud (b. 1952) joined the Science Museum in 1978 and has been Head of Life and Communications
Technologies group since 1994.
4 House of Lords, Select Committee on Science and Technology. (1998) Seventh Report: Resistance to Antibiotics and
Other Antimicrobial Agents. HL 81, 2 vols. London: HMSO.
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providing a vivid opportunity for Fleming, Florey and Chain5 to tell their stories, and
after the war numerous books told the story of Fleming’s fortunate encounter with
penicillin and several, if fewer, recounted in detail the work of the Oxford group. The
Americans, not to be outdone, also frequently told their side of the story. Of course,
this was not the end of the matter. How much credit should go to each of the
participants and this has been debated until recent days in the letter columns of the
New Scientist and in apparently endless streams of historical documentaries. I think a
new profession, ‘e x p e rt for historical documentary’, should be identified for the Census.
Naturally, the discovery of penicillin-G was an important event in itself. However, the
continuing interest it has held goes beyond that single drug. For penicillin-G was, of
course, the first of the fermentation-based antibiotics, the first antibiotic if one
excludes the sulphonamides. These other drugs, however, have experienced much less
historical attention, and it is really that hole that we wish to address today, at just that
moment when resistant organisms remind us how very dependent we are on
antibiotics, and people are indeed now talking about the end of the antibiotic age. Of
course, the whole story is very complex and much has happened in the United States,
the continent of Europe, and in Japan. I think of Watanabe’s work.6 So only one part
can be told by bringing together a group in this country. Nevertheless, today we can
recapture some of the issues, both those unique to this country and those experienced
worldwide. The afternoon will encompass the treatment both of new drugs and of
antibiotic resistance. I hope we will there f o re capture and understand better the
competition between the creativity of the chemists and of the bacteria, rather than the
h e roic story of the discove ry of a new drug and competition between people and germs. 
A few words, I hope, will link the history to the issues raised today. Ve ry shortly after
the announcement of penicillin, stre p t o m ycin was announced, and that entered the
m a rket in 1946. This development at the Rutgers Un i versity by Selman Waksman was
keenly watched in this country. For the first time, tuberculosis could be attacked
chemotherapeutically and we are fortunate that Douglas Eveleigh from the Wa k s m a n
In s t i t u t e7 has been able to join us. Of course, whereas the discove ry of stre p t o m ycin was
an American development, major contributions to its evaluation and exploitation we re
made in this country by Sir John Crofton, whom we are fortunate to have 
h e re, and others. Penicillin itself was developed with the Americans, first the 
5 Sir Alexander Fleming Kt FRCP FRS (1881–1955), Lord Florey OM Kt FRS (1898–1968) and Sir Ernst Chain
Kt FRS (1906–1979) shared the Nobel Prize for Physiology or Medicine in 1945 for the discovery and
development of penicillin. For further details on the making of the film, which is held by the Science Museum,
see Bud R. (1998) Penicillin and the new Elizabethans. British Journal for the History of Science 31: 305–333.
6 The original series of studies by T Watanabe and T Fukasawa appeared in Japanese in Medicine and Biology [Tokyo]
in 1960–1961 on resistance factors in Enterobacteriaciae. For later studies, published in English, see Watanabe T,
Fukasawa T. (1961) Episome-mediated transfer of drug resistance in Enterobacteriaciae. I. Transfer of resistance
factors by conjugation. Journal of Bacteriology 81: 669–678; idem II. Elimination of resistance factors with acridine
dyes. ibid. 81: 679–683; idem (1962) III: Transduction of resistance factors. ibid. 82: 202–209; idem (1962) IV.
Interactions between resistance transfer factor and F factor in Escherichia coli K-12. ibid. 83: 727–735.
7 Professor Eveleigh is at the New Jersey Agricultural Experiment Station of Rutgers, the State University of New
Jersey. See discussion on pages 6–7.
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m o re stable penicillin-V, which could be given by mouth. In the 1950s, howe ve r, a
g roup at Beecham developed the first semisynthetic penicillins based on 6-APA 
(6-aminopenicillanic acid), and they had been working with Chain in Rome on para-
aminobenzyl penicillin. How much was he their inspiration? Many of the key members
a re here today and can contribute. Perhaps we will learn more from them. Their work
led to the new penicillins immune to penicillinase, such as methicillin, and this helped
medicine cope with hospital-acquired infections with resistant staphylococci and one
question we may ask is how urgently did they feel the need to combat such organisms?
How urgent an issue for the team was the question of hospital-resistant staphylococci
in the late 1950s? Already by the early 1950s four bro a d – s p e c t rum antibiotics effective
against both gram-negative and gram-positive bacteria we re in common use –
t e t r a c ycline, Te r ra m yc i n ( ox y t e t r a c ycline: Pfizer), Au re o m yc i n ( c h l o rt e t r a c yc l i n e :
Lederle) and chloramphenicol. All these we re developed in the USA. Howe ve r, a new
family that emerged in the late 1950s was famously developed here – the
cephalosporins – and among the most interesting features in this development was the
role played by the National Re s e a rch De velopment Council (NRDC), which had been
set up in the late 1940s partly because of the debacle over the patenting of penicillin.8
In the House of Commons debates over the NRDC, the story of penicillin comes up
time and time again and we are fortunate to have the testimony of Dr Basil Ba rd who
p l a yed an important role in the patenting process. A distinctive feature of some of the
semisynthetic penicillins and the cephalosporins was their immunity to penicillinase
which had given a certain bacterial immunity and the first occasion of clinical
immunity to penicillin was as early as 1942. In 1947 Ma ry Ba r b er 9 found that 38 per
cent of strains of Staphylococcus aure u s we re penicillin-resistant, and more the follow i n g
ye a r, and we are fortunate to have with us several people who worked with Ma ry
Ba r b e r. Since then of course anxieties have increased. The emergence of the
semisynthetics in the late 1950s provided new weapons against penicillinase-pro d u c i n g
bacteria. By the mid-1960s, howe ve r, the methicillin-resistant bacteria had been
o b s e rved, and Go rdon St ew a rt – and we are fortunate to have him with us – pointed
out as early as 1965 that in academic circles resistance to penicillin has provoked about
as much interest as therapy.1 0 And, of course, this is even more true today. Ladies and
gentlemen, I think we are fortunate to have a ve ry rich feast laid out before us and 
I hope to have many fond assumptions ove rturned and others given some substance.
Booth: Well, thank you very much, Dr Bud, that’s a useful introduction to what we
are about today, and I think we should just go straight on to talk firstly about
8 The National Research Development Corporation (NRDC) was established in 1949, set up under the
Development of Inventions Act 1948 as a Corporation by the Board of Trade, to safeguard and commercialize
inventions arising principally from publicly funded research. op. cit. note 5 above.
9 Professor Mary Barber (1911–1965) was Professor in Clinical Bacteriology at the Postgraduate Medical School,
Hammersmith Hospital, London, from 1964 until her sudden death in 1965, where she had been lecturer from
1947 to 1948 and Reader from 1957 to 1964. See Barber M. (1947) Coagulase-positive staphylococci resistant to
penicillin. Journal of Pathology and Bacteriolog y 59: 373–384.
10 Stewart G T. (1965) The Penicillin Group of Drugs. Amsterdam: Elsevier. See biographical note 69 below.
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streptomycin and what happened there and I think Douglas Eveleigh would like
perhaps to start us off.
Professor Douglas Eveleigh:11 Well, first of all, thank you for inviting me. As you can
hear from my accent it’s not American, it’s Croynge, that is somewhere halfway
between Croydon and Penge. I have been at Rutgers now for 25 years, so I did meet
Selman Waksman, while Boyd Woodruff 12 is also a good friend and we’ve had
considerable historical discussions. Dr Waksman and Rutgers are famous for four
useful antibiotics: actinomycin, discovered in 1940 through Boyd Woodruff ’s PhD
studies, streptomycin in 1944 by Albert Schatz, and two antibiotics, neomycin in
1949 and candicidin in 1953, via Hubert Lechevalier’s studies. Four major antibiotics
and all from actinomycetes.13
Selman Waksman came to the United States from Russia, joined Rutgers, and received
his undergraduate degree in 1915, then studying soil protozoa and bacteria.14
Subsequently in his MSc in 1916, he focused very heavily on actinomycetes. At that
time it was ve ry clear that most microbiologists did not understand what
actinomycetes were. Actinomycetes were his solid base. He gained his PhD in
Biochemistry from the University of California in 1917, and wrote a text with
Davison on enzymes 15 – he had a heavy biochemical training. Dr Waksman returned
to Rutgers and remained there for the rest of his career. Most of his tenure was in the
classical Agricultural School. I am in the Agricultural School and I should just point
out to Robert [Bud] not at the Waksman Institute. I am an old Aggie. We have
friendly rivalry between the two groups. We always say ‘we’ found the antibiotics and
‘they’ spend the royalties. But to history.
11 Professor Douglas Eveleigh (b. 1933) has been Professor of Microbiology, Cook College, at Rutgers, the State
University of New Jersey, since 1970.
12 Dr Boyd Woodruff (b. 1917) was a graduate student of Waksman at Rutgers University from 1939 to 1942. His
1942 PhD thesis was ‘The production of antibiotic substances by soil microorganisms’. He then joined the Merck
Research Laboratory in Rahway, New Jersey, for a period of 40 years, heading research on natural products derived
from microorganisms. In retirement, in a home laboratory, he continues research on the ecology of soil
actinomycetes. He was elected to the US National Academy of Sciences in 1998. See Woodruff H B, Burg R W.
(1986) The antibiotic explosion. In Parnham M J, Bruinvels J. (eds) Discoveries in Pharmacology. vol. 3.
Pharmacological methods, receptors and chemotherapy. Amsterdam: Elsevier, 303–351.
13 See Waksman S A, Woodruff H B. (1940) The soil as a source of microorganisms antagonistic to disease-
producing bacteria. Journal of Bacteriolog y 40: 581–600. Schatz A, Bugie E, Waksman S A. (1944) Streptomycin,
a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proceedings of the Society
for Experimental Biology and Medicine 55: 66–69. Waksman S A, Lechevalier H A. (1949) Neomycin, a new
antibiotic active against streptomycin-resistant bacteria including tuberculosis organisms. Science 109: 305–307.
Lechevalier H, Acker R F, Corke C T, Haenseler C M, Waksman S A. (1953) Candicidin, a new antifungal
antibiotic. Mycologia 45: 155–171. 
14 Dr Selman Waksman (1888–1973) was born in Ukraine, and took US nationality in 1916. His 1916 MSc thesis
focused very heavily on actinomycetes. He became Professor of Microbiology at Rutgers University in 1930 and
was awarded the Nobel Prize in Physiology or Medicine in 1952 for his discovery of streptomycin. See Waksman
S A, Curtis R E. (1916) The actinomycetes of the soil. Soil Science 1: 99–134. Waksman S. (1954) My Life with
the Microbes. New York, NY: Simon and Schuster.
15 Waksman S A, Davison W C. (1926) Enzymes: Properties, distribution, methods and applications. Baltimore, MD:
The Williams & Wilkins Company.
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It’s very clear, as Boyd Woodruff has emphasized many times, that as soon as
Waksman heard of the effectiveness of penicillin, he returned to the lab and
completely changed the direction of his research.16 Up until that time, he was
extremely well known as a physiological soil microbiologist. He had been elected to
the US National Academy for his ‘m i c robiology of peat’ – really quite an
accomplishment. He was a soil microbiologist. But he switched research direction
from the fertility of soils and said, ‘We must now look at actinomycetes’ (of which he
had a vast collection) ‘and look for antibiotics’.17 That began with Boyd Woodruff ’s
study. Later with Albert Schatz, the programme was more rationally developed. 
I emphasize rational. Compare the new Rutgers’s screening system to the Dubos
studies in 1939 in which he discovered tyrocidine.18 Dubos would take bacteria, put
them in soil as a substrate, enrich for maybe a month then add a few more bacteria,
let it enrich for a further month, and then a few more. Clearly a long enrichment
procedure was considered essential. Waksman showed that the enrichment procedure
was not necessary: one could plate soil and directly screen the many hundreds of
cultures for antibiosis. This direct plating was a conceptual advance. So simplistic, but
so essential in large-scale screening. As noted previously the ingrained concept was
that one must perform long enrichment. Furthermore, Waksman also introduced the
use of Mycobacterium tuberculosis,19 to address these waxy gram-positive pathogens – 
a clinical development in a soil microbiological laboratory. The concept of the early
Rutgers’s antibiotic studies was to develop a facile screening methodology. Within that
screen they looked at productivity, and subsequently there was a clinical medical
programme including the use of animals. These were all critical points in the
development for actinomycete antibiotics, including streptomycin.
From that methodology one could search for other antibiotics and most subsequent
s c reens followed that model: isolate a diverse collection of soil microbes (especially
a c t i n o m ycetes), screen massive l y, plus, in industry there was considerable financial
backup for further analyses. In contrast, I assure you that Waksman did not have major
financial backing at that time: his was really quite a small programme. So point 1 was
16 See Woodruff H B. (ed.) (1968) Scientific Contributions of Selman A Waksman: Selected articles published in honor
of his 80th birthday, July 22, 1968. New Brunswick, NJ: Rutgers University Press.
17 Professor Douglas Eveleigh wrote: ‘Waksman had continually addressed the production of antimicrobial
products by soil microbes. Waksman’s first studies with actinomycetes were during World War I. International
communication was difficult and Krainsky’s cultures from Russia were unavailable. Krainsky was a pioneer in this
sphere. Waksman noted Krainsky’s publication “helped me greatly in my future work. ...In characterizing our
newly isolated cultures we tried to give Krainsky the maximum possible credit for his work.”’ E-mail to Mrs Lois
Reynolds, 3 November 1999. See Waksman S A. (1975) The Antibiotic Era. Tokyo: The Waksman Foundation of
Japan Inc. Quotations on pages 7, 8.
18 Dubos R J. (1939) Studies on a bacterial agent extracted from a soil bacillus. Jo u rnal of Experimental Medicine 7 0:
1 –17. Professor David Greenwood wrote: ‘René Dubos (19 0 1 –1982) had been a pupil of Selman Waksman but was
at the Rockefeller Institute when he discove red tyrothricin, the first true antibiotic, later shown to be a mixture of
two antibiotics, tyrocidine and gramicidin.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999. See Hotchkiss R D.
(1990) From microbes to medicine: Gramicidin, René Dubos and the Ro c k e f e l l e r. In Moberg C L, Cohn Z A. (eds)
Launching the Antibiotic Era. New York, NY: Rockefeller Press, 1–18.
19 op. cit. note 12 above.
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the development of a facile and rational screening method. Point 2, I think quite clearly
Waksman introduced the world to the use, the fuller potential, of the actinomyc e t e s .
They we re a re l a t i vely unknown group and I think we can extrapolate on that as we go
along. Point 3 was faith: penicillin and stre p t o m ycin we re dominant, and there was
absolute faith in them. Pa renthetically perhaps, the rapid rise of antibiotic re s i s t a n c e
was in part because there was such faith in, and use of, single antibiotics. 
But I will put faith in a further context. Boyd Woodruff tells me that at Merck they
developed the streptomycin system and that process went so well, they did not bother
to screen any other soils for further antibiotic producers. In fact the Merck research
focused on curing pernicious anaemia, a major disease, and thus their research was to
optimize vitamin B12 production via fermentation. One of the Merck fermentation
cultures produced the antibiotic grisein, which had been received from Donald
Reynolds, a Rutgers graduate student.20 Yet the focus on this culture at Merck was the
production of vitamin B12, not grisein. Perhaps the Merck decision was correct in that
grisein never made it to the market place, while the development of vitamin B12 by
Karl Folkers was a major achievement.21
I also mention one historical side of the story, which is not well known, regarding
streptomycin large-scale fermentation. Merck made their first streptomycin run in a
small pilot plant.22 It worked beautifully, but when they ran it again it failed. So they
ran it again and it failed, and again and again. They tried for six months and they did
not get another production run, due to ‘classical infections’. As a result, when the first
Merck large-scale fermentation tank was built, on the recommendation of Jackson
Foster, it had trays inside for surface culture in case the submerged fermentation could
not be solved. There was no impeller [stirrer]. Simply a stack of trays to grow the
m i c roorganisms in still culture. Finally Me rck worked out the mechanics of
submerged fermentation and bulk-scale streptomycin came to fruition, and the trays
were never used. 
Let me return to the faith Merck had in the new antibiotics, penicillin and
streptomycin. It was so strong that it was Parke-Davis, Lederle and other companies
that developed further antibiotics. Only then did Merck renew screening, presumably
based on the Rutgers system, and they soon discovered novobiocin. 
My fourth point is regarding the implications of industrial–university relationships.
Yes, in the 1940s there were such cooperative ventures. They were not a product of
the ‘New Biotechnology’. The implications of the Merck-Rutgers agreement are
20 See Waksman S A, Schatz A, Reynolds D M. (1946) Production of antibiotic substances by actinomycetes.
Annals of the New York Academy of Sciences 48: 73–86.
21 Wagner A F, Folkers K A. (1964) Vitamins and Coenzymes. New York, NY: Interscience Publishers.
22 Dr Boyd Woodruff wrote: ‘The Merck antibiotic fermentation referred to was penicillin and not streptomycin,
and the confusion is that the deep-tank fermentation was worked out first with the penicillin production and then
the expertise transferred to the streptomycin production.’ E-mail to Mrs Lois Reynolds from Professor Douglas
Eveleigh, 29 May 1999. For discussion on the introduction of the deep culture penicillin fermentation method to
Britain by Glaxo, see Davenport-Hines R P T, Slinn J. (1992) Glaxo: A history to 1962. Cambridge: Cambridge
University Press, 141–149, see also streptomycin development, 179–181. 
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important. In brief, Merck supported Rutgers’s research and for that support, Merck
had the rights to university results: as it turned out, for actinomycin and streptomycin.
Booth: Can I just get something clear here, because the patenting side of streptomycin
was rather important. Who held patents, were there any patents? Where were Rutgers
involved in that?
Eveleigh: The initial aspect was the agreement that Merck held the patents for all
rights.23 However, when streptomycin came along Waksman went back to Merck and
simply noted that conceptually ‘this discovery is major and could you change the
patent agreement?’ It was changed in two senses. One the university became the
beneficiary and secondly the university set up a non-exclusive licence. As such, seven
companies actually took out the licence at that time.
Booth: So it was free for anybody to get in on any act if they wanted to?
Eveleigh: Absolutely. Waksman said that he felt streptomycin was so important that
he wanted to ensure that it could be widely developed on a humanitarian basis. As
there could be a problem with production, he wanted development via a non-
exclusive rights agreement. This was practical at that time. Subsequently in hindsight
the non-exclusive rights decision has been criticized as not necessarily a well-founded,
wise decision. Thus when neomycin was discovered, there were several other
competing antibiotics ready for commercial development, and naturally an industrial
company wanted exclusive rights. In spite of that competitive commercial status, the
Rutgers patent policy did not change from a non-exclusive basis until 1976. Those 
are my four main points: the screening; the actinomycetes themselves; the complete
dominance and faith in one system; and then the implications for the non-exclusive
patent status.
Dr Milton Wainwright:24 Thank you, Doug, for that very good overview of the
situation. I would like to make a couple of comments. First of all, I would like to take
issue with the fact that Waksman was the first person to look at actinomycetes
antibiotics. In fact there had been some work by Belgian scientists Gratia and Dath 
in the 1930s,25 and also the Russians were quite active in the late 1930s looking at
23 Dr Boyd Wo o d ruff wrote: ‘Rutgers owned the patent on stre p t o m ycin. Me rck had the exc l u s i ve marketing rights. At
Wa k s m a n’s request, after stre p t o m ycin became famous, Me rck gave up its exc l u s i ve position, so marketing rights became
n o n - e xc l u s i ve. Me rck re c e i ved certain benefits for doing so by being able to deduct a portion of the initial deve l o p m e n t
costs from the royalty payments.’ E-mail to Mrs Lois Reynolds from Professor Douglas Eveleigh, 29 May 19 9 9 .
24 Dr Milton Wainwright (b. 1950) was appointed Lecturer at the University of Sheffield in 1975 and Senior
Lecturer in Microbiology from 1988. His interests include active research on unorthodox aspects of microbiology,
the history of antibiotics and the role of non-virus microorganisms in cancer aetiology. See Wainwright M. (1990)
Miracle Cure: The story of penicillin and the golden age of antibiotics. Oxford: Blackwell. 
25 See, for example, Gratia A, Dath S. (1924) De l’action bactériolytiques des streptothrix. Comptes Rendus Société
de Biologie 91: 1442–1443. See also Wainwright M. (2000) Andre Gratia (1893–1950): Forgotten pioneer of
research into antimicrobial agents including colicins. Journal of Medical Biography 8 (in press).
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actinomycetes. Some people have said one of the great advantages that Waksman had
was his ability to read Russian, and he may well have got many of his ideas from the
Russian literature. The name that comes to mind straightaway is a man called
Krassilnikov, who did a lot of work on actinomycetes.26
The other point that I think I would like to make is that we must emphasize the work
of Albert Schatz 27 in this. I think if we talk about Florey and Chain getting credit with
Fleming, then I think Schatz should get partial credit at least with Waksman, and also
the names of Feldman and Hinshaw must be included because they actually brought
the therapeutic potential of streptomycin into the fore. So my view of streptomycin is
not of an antibiotic discovered by Waksman, but one co-discovered by Waksman and
Schatz, and developed for medicine by Feldman and Hinshaw.28
Booth: Thank you very much. I think we might move on to the effect of streptomycin
on medicine. Sir John Crofton, you very kindly came to join us from Edinburgh and
I know you were one of the pioneers of using streptomycin. I don’t know whether you
actually carried out that first trial with Bradford Hill.
Sir John Crofton:29 I was a very junior person. The first trial was different in two 
ways I think. One was that it was the first well-known control trial of any therapy and
a model for all later trials. That was enormously important. I gather Philip D’Arcy
Hart30 had a trial in some other field, which was negative rather earlier on, but 
that tends to be forgotten. The other important thing was that it was the first 
really cooperative trial which occurred in many centres throughout the UK. My
function was a very junior one, I had been three months as a registrar at the 
Brompton and was then asked to coordinate the Brompton side of that trial. 
The control trial was ethically acceptable, because there was a limited amount of
26 K r a s s i l n i k ov N A, Ko reniako A I. (1938) The phenomenon of autobacteriolysis in Ac t i n o m ycetales. Mi k ro b i o l o g i i a 7:
708–720; 829–837. idem (1939) The bactericidal substance of the actinomycetes. ibid. 8: 673–685.
27 Dr Albert Schatz (b. 1920) was a PhD student of Waksman at Rutgers University from 1942 to 1945, and later
became a Professor at Temple University. See note 13 above. Schatz A. (1965) Antibiotics and dentistry. Part I:
Some personal reflections on the discovery of streptomycin. Pakistan Dental Review 15: 125–134. idem (1993) The
true story of the discovery of streptomycin. Actinomyces New Series 4: 27–39. We thank Dr Alan Yoshioka for
drawing our attention to these articles. For details of the case for Schatz’s recognition as co-discoverer of
streptomycin, see Wainwright M. (1991) Streptomycin: Discovery and resultant controversy. History and
Philosophy of the Life Sciences 13: 97–124.
28 Hinshaw H C, Feldman W H. (1945) Streptomycin in treatment of clinical tuberculosis: A preliminary report.
Proceedings of the Staff Meetings of the Mayo Clinic 20: 313–317. 
29 Sir John Crofton Kt FRCP (b. 1912) was Professor of Respiratory Diseases and Tuberculosis at the University of
Edinburgh from 1952 until his retirement in 1977. From 1947 to 1950, he worked part-time at the MRC
Tuberculosis Unit at the Brompton Hospital, London, and as Lecturer, later Senior Lecturer, at the Royal
Postgraduate Medical School, Hammersmith Hospital, London, from 1947 to 1951. He was a member of the
MRC Tuberculosis Chemotherapy Trials Committee from 1952 to 1963.
30 Dr Philip D’Arcy Hart CBE FRCP (b. 1900) trained in medicine at University College Hospital, London, where
he became a Consultant Physician. He was Director of the MRC Tuberculosis Research Unit from 1948 until his
retirement in 1965. See also note 54 below.
Post Penicillin Antibiotics
11
streptomycin,31 so it was ethically reasonable to randomize these advanced pneumonic
tuberculosis cases to a streptomycin and non-streptomycin group.32 The original idea
was that they should be treated for six months, but in fact resistance developed quite
quickly with subsequent deterioration in many patients. Before the trial was finished
the Medical Research Council (MRC) decided that this was only an adjunct to
treatment of tuberculosis and they reduced the treatment period to three months. It’s
interesting looking back at that. It’s interesting also to look at when resistance
developed. The World Health Organization (WHO) now accepts people into trials
and regards them as new patients if they have had less than a month of treatment,
assuming that no resistance could have developed. But if you look back at the original
streptomycin trial, and Denny [Mitchison] can probably tell us more about that,
several of the patients developed resistance really quite early towards the end of the
first month. That is something which we ought to remember.
B o o t h : When you say they became resistant, was this in a laboratory sense or a clinical one?
Crofton: In a laboratory sense and then deterioration, and that was why the MRC
subsequently controlled treatment. But of course there were quite a number of
successes. I had a letter from a patient just a month or two ago, who was in the original
streptomycin trial, and obviously survived. So there were some successes, but there
were a very appreciable number of failures.33 But fortunately PAS [para-aminosalicylic
acid] came the next year and the second trial was streptomycin alone, PAS alone, and
streptomycin plus PAS. The resistance rate came down and the failure rate came
down.34 Para-aminosalicylic acid was developed in Sweden.35 There was another 
little bit of serendipity in this first trial. We had quite a lot of patients after about six
31 Yoshioka A. (1999) Streptomycin, 1946: British central administration of supplies of a new drug of American
origin with special reference to clinical trials in tuberculosis, PhD Thesis, University of London. For details of the
constraints on the supply of streptomycin, see Hill A B. (1990) Memories of the British streptomycin trial in TB.
Controlled Clinical Trials 11: 77–79.
32 Medical Research Council. (1948) Streptomycin treatment of pulmonary tuberculosis: A Medical Research
Council investigation. British Medical Journal ii: 769–782. First controlled investigation of its kind to be reported
of 107 cases, admitted between January and September 1947, aged 15 to 25 (later 30), allocated on random
sampling basis to those receiving streptomycin in the form of hydrochloride (n=55) or bed rest only (n=52). Fifty-
one per cent (28) receiving streptomycin showed considerable improvement (‘a reasonable prospect of recovery’ by
radiological assessment) after six months, compared with eight per cent (4) of the control group on bed rest. Seven
per cent (4) of the streptomycin group died, compared with 27 per cent (14) of the control group.
33 op. cit. note 32 above.
34 Medical Research Council, Joint Subcommittee of the Streptomycin in Tuberculosis Trials Committee and the
Research Committee of the British Tuberculosis Association. (1950) Treatment of pulmonary tuberculosis with
streptomycin and para-aminosalicylic acid: A Medical Research Council investigation. British Medical Journal ii:
1073–1085. Three concurrent groups, aged 15 to 30, assigned by random selection: receiving PAS alone (P group,
n=59); streptomycin (sulphate) alone (S group, n=54); streptomycin plus PAS (SP group, n=53), accepted on the
trial between December 1948 and October 1949 for three-month treatment followed by a month of observation,
with two further months of additional treatment (collapse therapy or streptomycin). At the end of six months,
improvement was found in 56 per cent of the PAS group, 74 per cent of the S group and 87 per cent of the SP
group. Streptomycin-resistant strains were found in 33 of the 49 S patients and 5 of the 48 SP patients. 
35 Lehmann J. (1946) Para-aminosalicylic acid in the treatment of tuberculosis. Lancet i: 15–16.
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weeks who started vomiting. We thought that because it had occurred at that time this
might be an allergic reaction. We did a little double-blind trial at the Brompton, and
found that antihistamine drugs stopped the vomiting. Well, it soon disappeared as a
problem. It was obvious that this was due to a not very pure streptomycin. Somebody
else picked up our publication and this was the beginning of the anti-seasick treatment
with antihistamines, an interesting bit of serendipity. These are my main introductory
points. Of course, there were lots of later trials which we can comment on, and also
drug resistance. Denny Mitchison I am sure will talk about these.
P ro fessor D A Mitchison: 3 6 Now the question is do you want it put a little bit straighter
than Jo h n’s? I mean John has done a good introduction, but he has left out some ve ry
i m p o rtant things. The point that I wanted to make was that there we re two separate
studies, both started in 1947.37 One of these was the trial in pulmonary T B .38 The point
about that trial was that there was a limited amount of stre p t o m ycin available from Me rc k ,
and the MRC took the opportunity of doing a strict randomized comparison betwe e n
s t re p t o m ycin and just bed rest alone. Ot h e rwise one would have had no assessment of
s t re p t o m ycin, because all the American stre p t o m ycin went to individual physicians and no
scientific assessment was possible. This was really the start of the controlled clinical trial
that went all the way through medicine. T h a t’s the first really important point. 
Booth: Denny, can we just stop you one minute there. Who was behind that? Why
was it done?
Mi t c h i s o n :T h e re we re three people who we re the leaders in the study. Philip D’A rcy Ha rt ,
who was Se c re t a ry of the MRC Committee for St re p t o m ycin in Tu b e rculosis Tr i a l s .3 9 T h e
Tu b e rculosis Re s e a rch Unit (T RU) was partly at Mill Hill and partly in Ha m p s t e a d.4 0
Philip [D’A rcy Ha rt], its dire c t o r, went from one to the other. In the afternoon he trave l l e d
36 Professor D A Mitchison CMG FRCP FRCPath (b. 1919) was Professor of Bacteriology at the Royal
Postgraduate Medical School, Hammersmith Hospital, London, from 1971 until his retirement in 1985 (Emeritus
Professor until 1993) and Emeritus Professor at St George’s Hospital Medical School, London, since 1993. He was
Director of the Medical Research Council’s Unit for Laboratory Studies of Tuberculosis from 1956 until 1984, and
collaborated with the MRC Tuberculosis Research Unit (later the Tuberculosis and Chest Diseases Unit) in
developing effective chemotherapy for tuberculosis and research laboratories in East Africa, Madras, Hong Kong,
Singapore and Prague. He performed the laboratory tests for the 1948 Tuberculosis Chemotherapy Committee
Report and was a member of the 1952 Committee.
37 Medical Research Council, Streptomycin in Tuberculosis Trials Committee. (1948) Streptomycin treatment of
tuberculous meningitis. Lancet i: 582–596. Report on 105 cases of tuberculous meningitis and acute miliary
tuberculosis in young children aged nine and under and some adults, admitted between January and 18 August
1947, treated with streptomycin (hydrochloride), intramuscularly and intrathecally, for a minimum of 120 days.
Thirty-three per cent survived a minimum of seven months. Clinical work was coordinated by Dr Marc Daniels
and the pathological data was analysed by Dr Mary Barber.
38 op. cit. note 32 above.
39 op. cit. note 37 above and Appendix 2. 
40 Thomson A L. (1987) Half a Century of Medical Research. vol. 2. The programme of the Medical Research
Council (UK). London: MRC, 238–239. See also D’Arcy Hart P. (1999) A change in scientific approach: From
alternation to randomized allocation in clinical trials in the 1940s. British Medical Journal 319: 572–573.
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to Mill Hill and back, so he was working in both places. He was the driving force behind
the study, together with Ma rc Da n i e l s .41 Br a d f o rd Hi l l ,4 2 of course, was the statistician
and he insisted on randomized allocation. I think that’s probably the first time
r a n d o m i zed allocation was used. The patulin trial43 that came before this didn’t have
r a n d o m i zed allocation, so that it was a statistical innovation, but I think the re a l
p roblem was how you persuaded chest physicians, who we re not so easily persuaded by
science as they are nowadays, to actually consider treatment as a scientific adve n t u re .
The other study that went on at the same time was on the use of streptomycin in 
TB-meningitis and miliary T B .4 4 This was not a randomized trial, but one must
remember that these diseases we re 100 per cent fatal at the time. The finding that a
number of the patients surv i ved and did well in that trial spurred Me rck to go on
p roducing stre p t o m ycin in large amounts. The interesting thing too about this is that
w h e reas practically all the patients in the pulmonary TB trial developed drug re s i s t a n c e ,
ve ry few of those in the meningitis trial did so, presumably because the number of bacteria
in TB-meningitis is much smaller than in pulmonary TB. T h a t’s got a ve ry import a n t
t h e o retical implication, because at that time the people who thought about dru g
resistance thought in terms of one of two possibilities: either you had mutations followe d
by selection and the whole idea of mutation was really ve ry new, only really thought of in
the few years p re v i o u s l y, or it was an adaptation, which was Hi n s h e l w o o d’s idea.45 If it was
a d a p t a t i o n , then you should get drug resistance appearing in miliary and meningitis as 
well as in pulmonary TB, so it set the scene for mutation followed by selection, and that
was the t h e o retical basis on which the trial of stre p t o m ycin, PAS and stre p t o m ycin plus
PAS was set up. It’s ve ry important to get the theory right as well as the actual practice.
41 Dr Marc Daniels (1907–1953) joined what later became the MRC Tuberculosis Research Unit from 1948, with
Daniels as Deputy Director until his early death in 1953. He had been a Scholar to the Prophit Tuberculosis Survey
at the Royal College of Physicians from 1942 to 1945. He was appointed to the MRC Streptomycin in
Tuberculosis Trials committee as coordinator of its controlled clinical trials. See [unsigned with an appreciation
following by A B Hill]. (1953) Obituary: Marc Daniels. British Medical Journal i: 567–568. Anon. (1953) Marc
Daniels. Lancet i: 551–552.
42 Sir Austin Bradford Hill CBE Kt FRS (1897–1991) was Professor of Medical Statistics at the London School of
Hygiene and Tropical Medicine from 1945 until 1961. Doll R. (1994) Austin Bradford Hill. Biographical Memoirs
of Fellows of the Royal Society 40: 128–140. For details of Hill’s first attempt to introduce the concept of
randomization in controlled trials, see Wilkinson L. (1997) Sir Austin Bradford Hill: Medical statistics and the
quantitative approach to prevention of disease. Addiction 92: 657–666.
43 Medical Research Council, Patulin Clinical Trials Committee. (1944) Clinical trials of patulin in the common
cold. Lancet ii: 373–375. Clinical trials ran from December 1943 to April 1944, supervised by Dr Joan Faulkner.
For details of the earlier work, see Wilkinson L, Hardy A. (2000) Prevention and Cure: The London School of
Hygiene & Tropical Medicine. A twentieth century quest for global public health. London: Kegan Paul. Especially
chapter 7, ‘The wider spectrum of public health: Basic research in developing biochemistry; and applied science
and statistics in occupational health’.
44 op. cit. note 37 above. Medical Research Council, Streptomycin in Tuberculosis Trials Committee. (1950)
Streptomycin in acute miliary tuberculosis. Lancet i: 841–846.
45 Sir Cyril Hinshelwood FRS (1897–1967), physical chemist, was Dr Lee’s Professor of Chemistry at the Un i ve r s i t y
of Oxford from 1937 until his re t i rement in 1964. He was awarded the Nobel Pr i ze for Chemistry in 1956 jointly
with Nikolai Nikolaevich Se m e n ov (1896–1986) for his contributions to chemical kinetics. See Thompson H.
(1973) Cyril Norman Hinshelwood. Bi o g raphical Memoirs of Fe l l ows of the Royal Society 1 9: 375–431.
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Booth: Thank you very much indeed. The TB-meningitis work was Honor Smith46 
in Oxford?
Mitchison: Mary Barber, I think, at Hammersmith. [From the floor: St Mary’s] Well
it was several different places. 
Booth: And in other countries?
Mitchison: That was an MRC organization. It was a smallish group to start with,
Hammersmith, Liverpool and Glasgow to begin with, and then it expanded later to
Great Ormond Street and I am sure to Edinburgh and various other places. It got to
be a big study. And St Mary’s I am sure, yes. 
Booth: Did you all expect resistance to appear to streptomycin as it had with
penicillin? Was it expected or was it a surprise or how did people react?
Crofton: It was much worse than with penicillin. With penicillin there was sort of
ecological development of resistance in environments. With streptomycin it was in the
individual patient. So it was rather unexpectedly worse, because to begin with there
hadn’t been a great problem with penicillin.47
Booth: I think the other thing I would like to ask Professor Mitchison is one of the
key features of being able to look at the bacterium was being able to grow it. Was that
a major problem?
Mitchison: It was quite a problem to begin with. There was a small bacteriological
committee set up with Robert Cruickshank, who went to Edinburgh eventually, as
Chairman [of the Pathological Subcommittee of the MRC St re p t o m ycin in
Tuberculosis Trials Committee].48 I was a member of that very small group of 
four people at the very beginning of the pulmonary TB trial. It later expanded 
to be a big collaborative exercise. We were trying out the new Dubos media that 
had been worked out at the Rockefeller Institute, mainly of course by 
Middlebrook, not by René Dubos, and these actually were not the best methods to
46 Dr Honor Smith FRCP (1908–1995), neurologist, was physician in charge of Tuberculous Meningitis Unit,
Oxford, from 1948 until 1971. See Smith H V, Daniel P. (1947) Some clinical and pathological aspects of
tuberculosis of the central nervous system. Tubercle 28: 64–80. 
47 Crofton J, Mitchison D A. (1948) Streptomycin resistance in pulmonary tuberculosis. British Medical Journal ii:
1009–1015.
48 Professor Robert Cruickshank FRCP (1899–1974) was the first Director of the Central Public Health
Laboratory, Colindale, London, from 1945 until 1948. He was appointed Professor of Bacteriology at St Mary’s
Hospital Medical School, London, from 1949 to 1955 and Principal of the Wright–Fleming Institute of
Microbiology at St Mary’s from 1955 to 1957. He was Chairman of the MRC Pathological Subcommittee of the
Streptomycin in Tuberculosis Trials Committee. He moved to the University of Edinburgh as Professor of
Bacteriology in 1958 until his retirement in 1966. Professor D A Mitchison wrote: ‘As far as I can remember,
Robert Cruickshank used to be a Co-Professor with Alexander Fleming (they had tea at the opposite ends of a very
long table and appeared usually not to be on speaking terms!).’ Letter to Mrs Lois Reynolds, 29 March 1999.
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u s e .4 9 It just happened that they we re fashionable, just as many areas are 
now fashionable.
Booth: If I remember rightly you had a green-fingered senior technician who
happened to be able to do things that other people couldn’t, is that right?
Mitchison: I think all the people involved in the early work managed to get the
techniques to work, but they weren’t actually very efficient. This was the problem.
Crofton: Can I just comment on that particular point, because later on in 
Edinburgh we studied failures. We found we had some patients who had reason 
to have become streptomycin resistant, because of their previous treatment, and
behaved clinically as such, but the tests showed sensitivity. We found that the 
original Dubos [test] didn’t show up these low degrees of resistance to 
streptomycin which proved to be clinically significant and then the techniques 
were changed.
Mitchison: I don’t think that’s true. I think the actual situation was that the Tween 80
in the medium pushed the MICs [minimum inhibitory concentration (mg/ml)]
down. If one had used the right definition of resistance with the original Tween
medium, one would have detected these resistant strains.50
Crofton: I think we were using the same techniques and the same criteria of resistance
as you did.
Mitchison: And got equally bad or rather worse results.51
49 Professor D A Mitchison wrote: ‘Solid medium tests were almost universally adopted a little later on. What
happened worldwide was that sensitivity tests were originally set up in Tween albumen liquid medium (Dubos
media). There was then a move to the use of solid media, mainly because they were much easier to deal with and
far less often contaminated than the liquid medium tests. In most countries, the solid medium was
Löwenstein–Jensen egg medium and numerous problems arose with this because the activity of streptomycin was
greatly affected by the method of preparation of the medium, the size of the bottles, the volume on the slope, etc.
Thus, it was very difficult to standardize the tests. In America, some centres use agar-based media but these tend
to be much more expensive and also may be dangerous. There is a huge history of controversy about methods that
has gone on for years. Although there was this worldwide shift to solid media of various sorts, all of the recently
introduced automated systems for culturing mycobacteria (for instance the BACTEC system made by Becton
Dickinson Microbiology Systems) uses liquid media culture because of its greater sensitivity. The media never
include Tween 80.’ Letter to Mrs Lois Reynolds, 29 March 1999. For example, details on diagnostic microbiology,
see Richardson H. (1999) Blurring the boundaries. Chemistry and Industry (16.8.99): 625–630.
50 Professor D A Mitchison wrote: ‘Tween 80 is a surfactant which decreases the minimum inhibitory
concentration of many antituberculosis drugs.’ Letter to Mrs Lois Reynolds, 29 March 1999. See also Medical
Research Council, Pathological Subcommittee of the Streptomycin in Tuberculosis Trials Committee. (1948)
Specific laboratory tests in streptomycin therapy of tuberculosis. Lancet ii: 862–865.
51 Sir John Crofton wrote: ‘That’s why we changed the technique! – to make it concordant with clinical results.’
Letter to Mrs Lois Reynolds, 19 March 1999. Professor Mitchison’s response to this comment, dated 22 October
1999, and Sir John’s full letter will be deposited with the tapes, correspondence and other documentation from the
Witness Seminar in the Contemporary Medical Archives Centre of the Wellcome Library.
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Dr David Tyrrell:52 A point about the preceding placebo-controlled trial on patulin, as
a common cold treatment. It’s a long sorry story which we haven’t got time for now,
but people like Joan Faulkner supported D’Arcy Hart,53 ran round the country,
thousands of people were given patulin on a double-blind placebo-controlled basis.54
The only difference was that patients were not treated by random allocation, but as
alternate cases, but it was all under code so nobody could know which were given
patulin. This was essential as the results were entirely based on clinical assessment.
Previously there had been a Lancet report of a dramatically successful use of patulin
which, in retrospect, must have been due to faulty trial design; but Stuart-Harris 55 and
one or two others with practically no resources, had done another trial which showed
that it didn’t work. But this big trial carried conviction – patulin did no good. It was
earlier than the TB trial and I like to think of it as a good ‘dry run’. Probably people
like Bradford Hill looked at those results and said, ‘Well, would alternate cases be
really the best way of allocating the placebo and the controls?’ and therefore went one
step further and improved the design when it came to the TB trial. But of course that
trial also had the advantage that there were more objective assessments, blinded X-ray
assessment and so on. One other quickie, I think Sheffield was involved in the TBM
(tuberculous meningitis) trial because I remember doing the lumbar punctures. It was
a daily chore for the Professor’s house physician.56
Wainwright: Anyone who’s interested in the patulin trial, by the way, the Public
Record Office is just releasing a large archive on it, if you would like to research that,
it’s a very interesting story.
Going back to streptomycin. There’s a connection here between streptomycin and
penicillin. If you look at the Fleming archive, there are about six notebooks concerned
with streptomycin. I wonder if anyone remembers Fleming actually being involved? 
I would also like to ask the question, was the problem of streptomycin affecting the
eighth cranial nerve ever observed during the trials?
Crofton: Eighth cranial nerve damage came up very early, at the beginning. Also
patients often complained of paraesthesia around the mouth, but that tended to
52 Dr David Tyrrell CBE FRCP FRCPath FRS (b. 1925) trained in medicine at Sheffield and was Stuart-Harris’s
house physician from 1948 to 1949. He was a member of the scientific staff of the MRC Common Cold Unit at
Salisbury from 1957 and its Director from 1982 until his retirement in 1990, where he worked on antiviral drugs
in volunteers. From 1970 until 1982 he ran the Division of Communicable Diseases at the Clinical Research
Centre, Northwick Park Hospital, Harrow, where he was Deputy Director.
53 Dr Joan Faulkner (Lady Doll) was then Principal Medical Officer at the Medical Research Council. See D’Arcy
Hart’s biographical note 30 above.
54 op. cit. note 43 above.
55 Sir Charles St u a rt - Harris FRCP (1909–1996) was in the Royal Army Medical Corps at the time of the patulin trial.
He was Sir George Franklin Professor of Medicine at the Un i versity of Sheffield from 1946 until his re t i rement in 19 7 2 .
Stansfeld J M, Francis A E, St u a rt - Harris C H. (1944) Laboratory and clinical trials of patulin. L a n c e t i i: 370–372. Se e
Crane W A J. (1979) Professor Sir Charles St u a rt - Harris. Po s t g raduate Medical Jo u rn a l 5 5: 71–72. op. cit. note 43 above .
56 op. cit. note 37 above. 
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disappear with purer streptomycin.57
Booth: Was it recorded in the first clinical trial as a complication?
Crofton: Oh yes, I am pretty sure it was, because we did a lot of tests, but there was
little deafness. There was a later modification to streptomycin which produced more
deafness, if less giddiness, leading to its abandonment for clinical use.58
Dr Derek Bangham:5 9 In connection with some of the reactions to stre p t o m ycin, it might
be worth while drawing attention to the quality and potency of stre p t o m ycin. T h e
sterility of penicillins was tested on behalf of the Therapeutic Substances Re g u l a t i o ns 6 0 by
adding penicillinase which would knock out specifically penicillin, and then a sterility test
was done on what remained. But with stre p t o m ycin it was difficult because there was no
actual antagonist to stre p t o m ycin. Drs J W Lightbow n61 and John Cornfort h6 2 at Mill Hi l l
did eventually isolate a group of antagonists to stre p t o m yc i n .6 3 It was not used for a test.
Howe ve r, Lightbown then devised a test for sterility in which a solution of stre p t o m yc i n
was passed through a filter membrane, which was then cultured. Membranes invented by
El f o rd at the NIMR we re used at first.6 4 T h e reafter this test for sterility was used for all
antibiotics and made official in the British Ph a rmacopoeia 1963. 
I would like to mention other basic contributions that England made to antibiotics.
First was the problem of measuring preparations of penicillin, and the early penicillins
57 For a description of streptomycin’s toxicity and side-effects, see, for example, Barber M, Garrod L P. (1963)
Antibiotic and Chemotherapy. Edinburgh: E & S Livingstone Ltd, 98–101.
58 Sir John Crofton wrote: ‘The modification to streptomycin referred to was in fact dihydrostreptomycin.’ Letter
to Mrs Lois Reynolds, 2 November 1999.
59 Dr Derek Bangham FRCP (b. 1924) was Head of the Division of Biological Standards at the National Institute
for Medical Research (NIMR) from 1961 to 1972. He was later Head of the Hormones Division of the National
Institute for Biological Standards and Control (NIBSC), from 1972 to 1987.
60 Therapeutic Substances Regulations issued under the Therapeutic Substances Act 1925, revised 1956, related to
standards of strength, quality and purity of substances, and the tests to be used. 
61 Dr James W Lightbown was a member of the scientific staff in the Division of Biological Standards at the
National Institute for Medical Research (NIMR) from 1949 to 1972, and Head of the Division of Antibiotics at
the National Institute for Biological Standards and Control (NIBSC), Potter’s Bar, Hertfordshire, until 1983. 
62 Sir John Cornforth Kt CBE FRS (b. 1917) was a member of the scientific staff in chemistry at the National
Institute for Medical Research (NIMR) from 1946 to 1962. He became co-director of the Milstead Laboratory of
Chemical Enzymology of Shell Research Ltd and Associate Professor of Molecular Sciences at University of
Warwick from 1962 until 1975 when he was appointed Royal Society Research Professor at the University of
Sussex until his retirement in 1982, now Emeritus. In 1975 he shared the Nobel Prize for Chemistry with Vladimir
Prelog (b. 1906) for his work on the chemistry of enzyme action. 
63 See Lightbown J W. (1950) An antagonist of dihydrostreptomycin and streptomycin produced by Pseudomonas
pyocyanea. Nature 166: 356–357. Lightbown J W. (1954) An antagonist of streptomycin and dihydrostreptomycin
produced by Pseudomonas aeruginosa. Journal of General Microbiology 11: 477–492. Cornforth J W, James A T.
(1956) Structure of a naturally occurring antagonist of dihydrostreptomycin. Biochemical Journal 63: 124–130.
64 Dr William El f o rd FRS (1900–1952) was a member of the scientific staff of the National Institute for Me d i c a l
Re s e a rch from 1925 to 1952. Gradocol membranes or El f o rd membranes we re accurately graded collodion
membranes used to measure the size of small particles, such as viruses, before the advent of the electron micro s c o p e .
See Andrewes C H. (1952–53) William Joseph El f o rd. Ob i t u a ry Notices of Fe l l ows of the Royal Society 8: 149–158.
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we re rough stuff; the only way of assaying them was by biological assay developed by J H
Hu m p h rey and J W Lightbow n .6 5 Fo rtunately in 1944, Sir He n ry Dale had chaired an
international meeting to decide how to define the potency of penicillin. 
In his own words, ‘by judicious assembly of suitable persons’ at this international meeting,
under the League of Nations, it was decided to use international units. That unit was
based on the ‘Oxford unit’ .6 6 The problem with stre p t o m ycin was greater because that had
been developed in America, and all the Americans always insisted on talking about
m i c rogram equivalents of activity. You can’t talk about micrograms of activity.
Eveleigh: You [Booth] commented ‘was resistance expected?’ and I think scientists
delude themselves. The answer is clearly that Ehrlich showed there was resistance back
b e f o re 1910 to a whole range of drugs. He showed there was combined resistance to
d rugs back in 1910. Penicillin resistance was shown in 1942, sulphonamide re s i s t a n c e
was shown in 1942 and stre p t o m ycin was first really used in 1946 and resistance was
s h own in 1946.6 7 So I think we shouldn’t be deluded about where we are coming fro m .
Mitchison: It was certainly one of the major aims of the first bacteriological group to
look for drug resistance, and I am also quite sure that these very early reports of
streptomycin resistance were already known by the time that the work started, so I
don’t think there was anything new.
Booth: St Mary’s was mentioned. Keith Rogers was at St Mary’s in the earlier phase,
but was Mary’s involved in streptomycin, and did Fleming have any attitude to it?
Dr Keith Rogers:68 I was a long, long way from St Mary’s at that time. I left at the
end of the blitz.
65 Humphrey J H, Lightbown J W. (1952) A general theory for plate assay of antibiotics with some practical
applications. Journal of General Microbiology 7: 129–143.
66 The ‘Oxford unit’ of activity, described as 0.6 µg of pure penicillin-G, was defined by the standard developed by No r m a n
Heatley for penicillin. See St ew a rt (1965) op. cit. note 10 above, page 9. See He a t l e y’s biographical note 146 below.
67 Youmans G P, Williston E H, Feldman W H, Hinshaw H C. (1946) Increase in resistance of tubercle bacilli to
streptomycin: A preliminary report. Proceedings of the Staff Meetings of the Mayo Clinic 21: 126–127. We thank Dr
Alan Yoshioka for drawing our attention to this reference.
68 Dr Keith B Rogers (b. 1910) worked with Fleming (op. cit. note 5 above) at St Ma ry’s Hospital, London, fro m
1935 to 1941. Dr Keith Rogers wrote: ‘I felt I could not put myself forw a rd as the easily caught guinea-pig, but
Fleming used me, as a most willing subject. He was always ready to check if he could, to see if one of his ideas would
w o rk. He had some stre p t o m ycin which he must have been sent, well before it became generally available. In Au g u s t
1946 I was about to be posted to Venice after my entry into the RAMC [Royal Army Medical Corps], when I
d e veloped an acute antral infection. I was in London and visited my old friends in the Inoculation De p a rtment who
obtained a heavy pure growth of Haemophilus influenza f rom my post nasal discharge. Fleming suggested that he
would get Simpson, the Ma ry’s ENT surgeon, to wash out the antrum and then instil some stre p t o m yc i n .
Un f o rtunately I must have been sensitive to the stre p t o m ycin, or the vehicle in which it was placed, as overnight the
a n t rum blocked and probably eve rything inside expanded to build up a huge pre s s u re causing seve re pain and swe l l i n g
of that side of my face. Simpson washed the antrum out the next morning and there was no further trouble. T h i s
must have been an early use of stre p t o m ycin, but I felt it was too trivial to talk about.’ Letter to Sir Christopher Booth,
13 May 1998. For details of Dr Ro g e r s’s account of a similar experience with penicillin in 1932, see Selwyn S. (1980)
The Beta-Lactam Antibiotics: Penicillins and cephalosporins in perspective . London: Hodder and Stoughton, 22–23.
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Professor Gordon Stewart:69 I was at St Mary’s at that time, and certainly cases were
being treated. In fact, one of the events in the late 1940s, which made a more
convincing impact than almost any other was the cure of childhood tuberc u l o u s
meningitis, with stre p t o m ycin given intrathecally as well as intramuscularly. Be f o re that
the difficulty was that there was little or nothing to compare it with. T h e re was no other
d rug. A bit of history: Domagk in Germany had found that thiosemicarbazo n e s had 
a distinct effect upon tubercle bacilli in vitro. The Germans were using them for the
treatment of tuberculosis. We tried some in guinea-pigs, mice and monkeys,
ultimately comparing it with streptomycin.70 The difference was striking, in that
although the thiosemicarbazones had a therapeutic action, they didn’t compare
with streptomycin, and the toxicity was far too high. So they dropped by the wayside,
although these were by no means without activity, and some day we might have to use
this chemical lead again, because synthetic antimicrobials have been more useful 
than antibiotics in the therapy of tuberculosis.
Professor Alan Glynn: 71 I was Senior Registrar on the ward where tuberculous
meningitis had been treated at St Mary’s. By that time the trial was all over and
everything was accepted but there were still a small trickle of patients with tuberculous
meningitis coming in. Fleming had just died. Whether he had been involved with
them I don’t know. I really remember it from the fact that we also gave streptomycin
occasionally intracisternally and I had to do this the first time with just brief verbal
instructions from Dickson Wright an hour before.72 The patient wasn’t frightened,
because he was too ill, but I was. 
Booth: If I remember rightly, Alan, at some stage in the treatment of tuberculous
meningitis people started using large doses of tuberculin intrathecally as well to
promote reactions. Would anybody like to comment on that?
Crofton: That was at Oxford. That was Honor Sm i th73 and they set out to do a trial on
this, in tuberculosis in general, in South Africa, and I went out with that group to help
69 Professor Gordon Stewart (b. 1919) was Professor of Public Health at the University of Glasgow from 1972 until
his retirement in 1984, now Emeritus. His long professional interest is in the control of communicable diseases
which began with his work with antibiotics in 1944 at the Royal Naval Medical School, Haslar, Portsmouth. See
Stewart (1965), note 10 above.
70 Ge r h a rd Johannes Paul Domagk (1895–1964) was Di rector of the I G Farbenindustrie Laboratory of Ex p e r i m e n t a l
Pathology and Bacteriology from 1927. He was awarded the Nobel Pr i ze for Physiology or Medicine in 1939, although
his acceptance was cancelled by the German Government. He re c e i ved the award in 1947, but not the monetary Pr i ze .
71 Professor Alan Glynn FRCP FRCPath (b. 1923) practised clinical medicine at St Mary’s Hospital, London, from
1956 to 1958. He took up bacteriology at St Mary’s, was appointed Professor in 1971 and Head of Department
of Bacteriology in 1974. In 1980 he became Director of the Central Public Health Laboratory at Colindale until
his retirement in 1988.
72 Mr Arthur Dickson Wright FRCS (1897–1976) was Consulting Surgeon at St Mary’s Hospital, London, from
1927 until his retirement in 1962 and the Prince of Wales General Hospital, London. He was on the Council of
the Royal College of Surgeons of England for 16 years from 1952, becoming Vice-President.
73 op. cit. note 46 above. 
Post Penicillin Antibiotics
20
o r g a n i ze it. Un f o rt u n a t e l y, Cairns,7 4 who was the leader, who was a professor of
n e u ro s u r g e ry in Oxford, developed leukaemia just after he came back and so it all folded
up and, I believe, that trial was never done. I don’t think it would have worked anyway.75
Booth: Did it ever work? Nobody ever believed in it, did they?
Crofton: With the later success of combined treatment using streptomycin with PAS
and/or isoniazid, it is understandable that additional tuberculin treatment was not pursued.
Booth: Now at what stage did PAS come in, and none of you have mentioned INAH.
What was the function of INAH?76
Crofton: I think the PAS trials were started in 1948.
Booth: Why? What was the rationale behind it?
C ro f t o n : PAS was actually discove red before stre p t o m ycin, but not publicized. It
became available in 1948. It was evo l ved by Lehmann in Swe d e n .7 7 The rationale was
that aspirin had been shown to stimulate the metabolism of the tubercle bacillus.
Lehmann speculated that an alteration of the aspirin molecule might inhibit an
essential metabolic pathway. The para-amino form of salicylic acid proved to do so. T h e
first MRC trials, having produced all this resistance, they initiated this triple trial, as
Denny and I have mentioned – stre p t o m ycin alone, PAS alone and the combination.7 8
With the combination there was considerably less resistance and less failure. And then
in 1952 isoniazid came up and so that was tried up against stre p t o m yc i n / PA S .7 9
74 Sir Hugh Cairns FRCS (1896–1952), an Australian neurosurgeon, held the Nuffield Chair of Su r g e ry at Oxford
Un i versity from 1937 until his early death in 1952. During the war he became the first adviser to the Mi n i s t ry of He a l t h
on head injuries, organized the Head Injuries Hospital in St Hu g h’s College, Oxford, and was Consultant Ne u ro s u r g e o n
to the Army with the rank of Br i g a d i e r. He and Fl o rey organized the field trials of penicillin in No rth Africa in 1943.
75 Sir John Crofton wrote: ‘As far as I remember we were primarily planning to see if the use of tuberculin would
improve the results in the treatment of pulmonary tuberculosis. I think we outlined the components of such a trial
but, for the reasons I stated, do not think they got as far as any final protocol or formed an actual trial.’ Letter to
Mrs Lois Reynolds, 19 March 1999. See Cairns H, Duthie E S, Smith H V. (1946) Intrathecal streptomycin in
meningitis: Clinical trial in tuberculous, coliform and other infections. Lancet ii: 153–155.
76 Isoniazid (isonicotinic acid hydrazide – INAH) was first synthesized in 1912 and is often a primary drug for
treatment of tuberculosis. In 1952 three isoniazid products were under trial in Britain: Rimifon, Roche; Nydrazid,
Squibb; Pycazide, Herts Pharmaceuticals. Anon. (1952) Notes and News: Isonicotinic acid derivatives in
tuberculosis. Lancet i: 571. See Fox H H. (1953) The chemical attack on tuberculosis. Transactions of the New York
Academy of Sciences 15: 234–242.
77 op. cit. note 35 above.
78 Medical Research Council, Joint Subcommittee of the Streptomycin in Tuberculosis Trials Committee and the
Research Committee of the British Tuberculosis Association. (1950) Treatment of pulmonary tuberculosis with
streptomycin and PAS. A Medical Research Council investigation. British Medical Journal ii: 1073–1085. 
79 Medical Research Council, Tuberculosis Chemotherapy Trials Committee. (1952) The treatment of pulmonary
tuberculosis with isoniazid. An interim report to the Medical Research Council. British Medical Journal ii:
735–746. idem (1953) Isoniazid in combination with streptomycin or with PAS in the treatment of pulmonary
tuberculosis. ibid. ii: 1005–1014. idem (1955) Various combinations of isoniazid with streptomycin or with PAS
in the treatment of pulmonary tuberculosis. ibid. i: 435–445.
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Booth: And isoniazid was known in the laboratory to have antituberculous effects or
not? Why was it introduced? There must have been some reason.
Crofton: It was the result of Domagk’s work in Germany. All the German patents
were disallowed at the end of the war, and both the Americans and the Swiss
developed isoniazid from Domagk’s work. I think I am correct. 
Booth: Let’s move back to Professor Mitchison, with your bugs in your laboratory.
Here you have got PAS and INAH, and everybody says, ‘OK this is stopping
resistance’, so how did that happen? What did it do?
Mitchison: Well, the idea was that you have mutations to, say, streptomycin resistance,
occurring rarely, one in perhaps 107; you have resistance to PAS in say one in 106.
To have double resistance to both of these would be one in 1013 bugs, and that’s more
than you would actually get in the lungs. It doesn’t work quite like that because
streptomycin is not a very good anti-TB drug and some multiplication goes on 
despite its presence, and the same is certainly true of PAS. You really have to wait until
you get to isoniazid to have a very much better drug. Isoniazid was originally
developed in America, but it’s been through the hands of other laboratories. It
had been through the hands of Burroughs Wellcome pharmaceutical company [The
Wellcome Foundation] in this country and was missed as an antituberculous 
drug. They used the wrong test organism. That’s a very sad story, but it’s true. It
was screened in the right way in America and brought out in 1952 with a great 
burst of publicity. It went immediately, as far as this country went, into MRC
studies both of isoniazid alone and then isoniazid in combination with PAS and/or
streptomycin over a period of several years.80
Dr Alan Yoshioka:81 A comment on St Mary’s Hospital. Fleming was actually Chair of
a much lesser known MRC Committee on the use of stre p t o m ycin in 
n o n - t u b e rculous conditions. These included typhoid feve r, Haemophilus 
i n f l u e n z a e meningitis. It was also tried at St Ba rt h o l o m ew’s and at several 
other centres.82
I take issue with the statement that all the supplies in the United States were
allocated to individual physicians. There was a very large programme organized by
the Committee on Chemotherapeutic and Other Agents of the National 
Research Council and doctors such as Feldman and Hinshaw who were involved in
80 op. cit. note 79 above.
81 Dr Alan Yoshioka (b. 1963) was awarded his PhD for his thesis on streptomycin by the University of London
shortly after this seminar, see note 31 above. See also Yoshioka A. (1998) Use of randomization in the MRC’s
clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. British Medical Journal 317: 1220–1223.
82 Wilson C. (1948) St re p t o m ycin in non-tuberculous infections: Su m m a ry of a re p o rt to the Medical Re s e a rch Council.
L a n c e t i i: 445–446. Sir Alexander Fleming was Chairman of this MRC Committee and Professor Clifford Wilson, 
Professor of Medicine at the Un i versity of London and Di rector of the Medical Unit at the London Hospital, was Se c re t a ry.
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quite a large programme which was funded by industry, a large consortium of
manufacturers.83
P ro fessor Graham Ay l i f fe :8 4 Can I just make a comment on other uses of
streptomycin? When I was a house surgeon in the mid-1950s, penicillin and
streptomycin were widely given for surgical infections. I wonder whether this
combination was really very effective, as it has been shown in recent years that
Bacteroides is one of the main causative organisms of surgical infections and is usually
resistant to both antibiotics. The other use of these agents is, of course, for bacterial
endocarditis. Penicillin–streptomycin was used successfully as a synergic combination
for many years, particularly for enterococcal infections. I wonder whether we could
persuade Pamela Waterworth to say something about this. Professor Garrod and Miss
Waterworth were particularly interested in the treatment of endocarditis.85
Miss Pamela Waterworth: 86 I am sure that there can be a synergic effect between
penicillin and streptomycin, but this is only of significance when the treatment needs
to kill all the infecting organisms present. Penicillin alone always leaves a few
[bacterial] survivors, which are normally disposed of by the body’s natural defences. If
this does not happen, the infection recurs when treatment is withdrawn. The main
example of this is the treatment of bacterial endocarditis due to enterococci or other
relatively resistant streptococci. The organism needs to have normal sensitivity to
streptomycin, then the synergic effect of this (or indeed other aminoglycosides) with
penicillin normally produces total bactericidal action in vitro, and frequently succeeds
in treatment.
At Bart’s we did have some evidence of the efficacy of this many years after the
i n t roduction of stre p t o m ycin, when we had a patient with an entero c o c c a l
endocarditis, and his streptococcus was highly resistant to streptomycin, and I could
83 The Committee on Chemotherapeutic and Other Agents was one of the National Research Council’s medical
subject committees, created in World War I to advise the US Government’s military on scientific and technological
matters. For the large-scale trials run by the US Public Health Service and Veterans’ Administration after the report
of Hinshaw and Feldman’s research in 1945 (op. cit. note 28 above), see Marks H M. (1997) The Progress of
Experiment: Science and therapeutic reform in the United States, 1900–1990. Cambridge: Cambridge University
Press. See Chapter 4, ‘ War and peace’, pages 98–128, especially 113–116.
84 Professor Graham Ayliffe FRC Path (b. 1926) was Professor of Medical Mi c robiology at the Un i versity of Bi r m i n g h a m
f rom 1980 until his re t i rement in 1990, now Emeritus. He was a member of the scientific staff at the Medical Re s e a rc h
Council and Consultant Bacteriologist at the Hospital Infection Re s e a rch Laboratory, Birmingham, from 1963 to 1994.
See Low b u ry E J L, Ayliffe G A J. (1974) D rug Resistance in An t i m i c robial T h e ra py. Sp r i n gfield, IL: Charles C T h o m a s .
85 Professor Lawrence P Ga r rod FRCP (1895–1979) was Professor of Ba c t e r i o l o g y, Un i versity of London, from 1934
until his re t i rement in 1961, when appointed Emeritus. After re t i rement he was made Ho n o r a ry Consultant in
Chemotherapy at the Royal Postgraduate Medical School, Hammersmith Hospital, London. He had been
Bacteriologist at St Ba rt h o l o m ew’s Hospital, London, from 1925 to 1961. He was an original member of the MRC ’s
Penicillin Clinical Trials Committee. See Shooter R A. (1984) Lawrence Paul Ga r rod. Mu n k’s Ro l l 7: 203–204. 
86 Miss Pamela Waterworth (b.1920) worked with Professor L P Garrod at St Bartholomew’s Hospital, London,
from penicillin’s introduction in 1944 until his retirement in 1961. She then joined Mary Barber at the Royal
Postgraduate Medical School, Hammersmith Hospital, London. In 1971 she moved to the Department of
Microbiology at University College Hospital, London, until her retirement in 1981.
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get no enhanced killing effect with penicillin and streptomycin. We treated the patient
with a very full course, a long course, of high-dosage penicillin, and unfortunately his
blood culture became positive about three weeks later with the same organism. Then,
the only suggestion we had was the use of neomycin instead of streptomycin, because
I had in fact demonstrated that whereas streptomycin did nothing to help kill the
streptococcus, neomycin produced a very excellent synergic effect. The patient was, of
course, told that if he had neomycin that he would be deaf after it, but he chose to be
deaf. We did give him a course of the combined treatment, he was cured of his
infection, but he was stone deaf after his treatment. This was published by Professor
Garrod in the British Medical Journal under the title of ÔDeaf or deadÕ. 87 And I think
that is evidence that there is an effect, a genuine effect, in certain circumstances,
between the two drugs.
Dr Ralph Batchelor:88 I wonder how much it was rea l i zed, and I suspect not at all at
that time, that there was interaction between the penicillin molecule and the
a m i n o g l ycosides, because b-lactams can acylate the amino groups of
a m i n o g l ycosides, particularly when the two are together in high concentration
making them pharmaceutically incompatible. If you left the two together for any
length of time before giving them to the patient, you would be giving part i a ll y
i n a c t i vated drugs leading to treatment failures, the cause of which was not
understood in the early days. 
Crofton: Penicillin and streptomycin combination was used very extensively for
respiratory infections in the Third World. This was always a worry, because if there
was cryptic tuberculosis, you might be getting streptomycin resistance, so there was a
lot of propaganda against this use. I think it is not widely used now. Some people also
thought it was effective in bacterial endocarditis.89
Professor Harold Lambert:90 I think one interesting general point about these years
is the time it takes, even after persuasive trials are published, before these new drugs
supplant other treatments. I was registrar of a chest department at University College
87 Havard D W H, Garrod L P, Waterworth P M. (1959) Deaf or Dead? A case of subacute bacterial endocarditis
treated with penicillin and neomycin. British Medical Journal i: 688—689.
88 Dr Ralph Batchelor (b. 1931) was a biochemist at Beecham Research Laboratories, Betchworth, Surrey, from
1956, working his first year in Rome with Professor Sir Ernst Chain. He moved from research to general
management in 1970 and was a Director of Beecham Pharmaceuticals from 1978 until his retirement in 1989. He
was awarded the Addingham Medal by the City of Leeds in 1966 and the Royal Society Mullard Medal in 1971.
Some of the first crystals and early chromatograms showing the presence of 6-APA are in his original notebook,
now on display in the Science Museum. See Batchelor F R, Doyle F P, Nayler J H C, Rolinson G N. (1959)
Syntheses of penicillin: 6-aminopenicillanic acid in penicillin fermentations. Nature 183: 257—258.
89 
op. cit. note 87 above.
90 Professor Harold Lambert (b. 1926) trained as a physician, with spells of microbiological research. He was
physician in charge of the infectious diseases department at St GeorgeÕ s Hospital, London, from 1965, later
Professor from 1972, until his retirement in 1984. He has been Visiti g Professor at the London School of Hygiene
and Tropical Medicine since 1984.
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Hospital in 1955–56, and still did 2000 pneumothorax refills; 91 this was of course
three years after isoniazid and more years after streptomycin and PAS, and it often
takes quite a time of years before the new drugs are seen in relation to pre-existing
treatment. It rather reminds me of the meningococcal problem. If one looks at the old
1930s papers, antimeningococcal sera were used in conjunction with sulphonamides
in thousands of cases, the serum having been introduced by Flexner in 1908.92 Only
after people got confidence in the sulphonamides, because of course at that time
meningococci were all sulphonamide susceptible, did the serum fade away.
Booth: If you were doing pneumothoraces, you were probably doing them in a
separate clinic, with personnel who were afraid of losing their jobs. Why didn’t they
give them up?
Lambert: I think it was a question of duration. John Crofton will correct me on this,
but I think in the early years what was uncertain was relapse rates in relation to
durations of therapy. That’s my hunch; people didn’t really quite have the confidence
to say ‘that was it’ when you gave a particular course of treatment, but Denny
[Mitchison] and John [Crofton] would know more about this than I would.
Crofton: Well a lot of people were not getting very high cure rates, because first of all
they didn’t go on long enough. We very early analysed our relapse rates, and
discovered that if you gave 18 months or more with the old three drugs you didn’t get
relapses and you did cure them. I went to Edinburgh at the beginning of 1952 and
we never did a pneumothorax after that. And it took about 20 years, before most chest
physicians in the UK were giving good tuberculosis treatment.
Booth: Was it because their livelihoods were at stake?
Crofton: Oh no, it was just conservatism.
M i t c h i s o n : Well, there’s a ve ry much more fundamental point than this, that there are
some drugs to which a high pro p o rtion of the bacterial population is seen to be
phenotypically resistant. This is true of the aminoglycosides, they are singularly ineffective
against persisting tubercle bacilli. I wouldn’t like to say what they do about enterococci, I
am just talking for the moment about TB. Isoniazid is a bit better, but it’s not ve ry good,
and PAS is hopeless. Now, no drug actually kills all the tubercle bacilli in lesions. You do
n e ver get a complete cure in tuberculosis. All you do is to bring the number of persisting
bacilli down to the level at which immunity can hold them and that’s all you can do.
91 The reversal of ‘collapse therapy’, or closure of tuberculous cavities through relaxation of the lung, used a number
of methods, including artificial pneumothorax. By 1960, for those with resistance to the standard drugs
(streptomycin, PAS and isoniazid) or who failed to comply with treatment, the treatment of choice was pulmonary
resection of the lesions. See, for example, Davidson S. (1961) The Principles and Practice of Medicine: A textbook
for students and doctors. Fifth edition. Edinburgh: E & S Livingstone Ltd, 387–388.
92 Flexner S, Jobling J W. (1908) An analysis of 400 cases of epidemic meningitis treated with the anti-meningitis
serum. Journal of Experimental Medicine 10: 690–733.
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Tyrrell: I was at the Northwick Park Hospital, doing infectious diseases and treating
tuberculosis, but I have a feeling that we went on treating with streptomycin and PAS,
in triple therapy, after a lot of other people had changed to rifampicin.93 The reason
was, that there were clinical trials that said, provided you did your triple therapy
properly, you got long-term clinical recovery, never mind whether or not a few
organisms were alive. I was prepared to persuade patients to put up with the injections
so I could say, ‘And if you stick with it, you are going to have a solid clinical cure’; let
other people see whether rifampicin and the other combinations of drugs will do
equally well. I think it is not a term really of abuse to say that’s conservative, I think
that is careful therapy.
Dr Geoffrey Scott:94 It may be of interest that the current consultants in a very
famous neurological hospital not a million miles from here are still convinced that
streptomycin is a mainstay of the treatment of tuberculous meningitis, which it
probably is not.
Booth: That’s the National Hospital [for Nervous Diseases] at Queen Square, I
presume you are referring to. Well, on that note I think we should move on. We have
got other things to discuss and I think we should go on to semisynthetics at this stage.
Dr Peter Doyle:95 What I propose to do is to set the scene, since I was personally
involved in it. To set the scene properly for Beecham’s involvement in this story, we
need to go back to 1947. In 1947 Mr Lazell, who later became the Chairman of the
Beecham Group, decided that it was about time Beecham’s had a research group, so
he bought an old house in the midst of Surrey, Brockham Park, and set up a central
research group there.96 Initially that was a general purpose research group, that did all
sorts of things, studied the effect of light on the colour of Lucozade, studied the use
of cysteine in Silvikrin hair tonic, and various things of that sort. One of the
interesting points was that it was officially opened by Sir Alexander Fleming in 1947.
Now this might have been a coincidence, but there was no doubt that his shadow fell
over Brockham Park for some years afterwards. I joined the company in 1952 when
the labs had been going for about five years and by which time they had moved more
93 Rifampicin, one of 500 derivatives of rifamycin (introduced into therapy in 1968), was considered to be an
improvement on the standard triple therapy of streptomycin, PAS and isoniazid, as it could be taken orally with
improved antibacterial activity. See, for example, Garrod L P, Lambert H P, O’Grady F. (1973) Antibiotic and
Chemotherapy. Fourth edition, Edinburgh: Churchill Livingstone, 220, 446. For the nomenclature of the
rifamycins, see Aronson J. (1999) When I use a word... That’s show business. British Medical Journal 319: 972.
94 Dr Geoffrey Scott (b. 1948) has been Consultant Clinical Microbiologist at University College London
Hospitals since 1984. His main preoccupation is the inexorable rise in antibiotic resistance. 
95 Dr Peter Doyle OBE (b. 1921) has been a chemist in industry since graduating from the University of London
in 1944. He joined Beecham Laboratories in 1952 and was Director of Research of Beecham Pharmaceuticals from
1962 until his retirement in 1983. Among other honours, he received the Worshipful Society of Apothecaries Gold
Medal in Therapeutics in 1964 jointly with Dr G N Rolinson (op. cit. note 101), the Royal Society Mullard Medal
in 1971 jointly with Dr Ralph Batchelor (op. cit. note 88), Dr J H C Nayler (op. cit. note 102) and Dr Rolinson.
He was awarded the OBE for services to the pharmaceutical industry in 1977.
96 Lazell H G. (1975) From Pills to Penicillin: The Beecham story, a personal account. London: Heinemann.
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in the direction of what we used to call ‘ethical pharmaceuticals’, but we now call
prescription medicines. Mr Lazell felt that the introduction of the National Health
Service in 1948 was going to destroy the over-the-counter pharmaceutical business
and, as you probably realize, Beecham had a big commercial interest in Beecham’s
Powders, Beecham’s Pills, Veno’s Cough Cure etc. You name it, they were all on the
shelves in Boots. By 1952 the emphasis was changing, and it was decided we ought to
be doing more on research into new prescription medicines. 
At the time I joined the company in 1952 as Head of the Chemistry Department, it
consisted of three graduates and about four technicians. My ex-colleague, David
Brown, joined at the same time as Head of Pharmacology and he set up the first
pharmacology department. For the first three years, between 1952 and 1955, our
main work was confined to compounds related to atropine, because we were interested
in problems of gastric and duodenal ulcers, and also in antitubercular compounds.
David Brown set up an animal house and we were using the conventional 21-day
mouse test, using H37RV.97 For those who have just been talking about streptomycin,
it might be interesting that the compounds we were working with, were derivatives of
British anti-Lewisite (BAL).98 British anti-Lewisite has good antitubercular activity,
but it is a foul-smelling compound. At the same time Dr Snow and his colleagues at
ICI were working on derivatives of ethylmercaptan (diethyl disulphide). We were both
working on extremely smelly compounds. We got as far as considering a clinical trial,
but the human experiments we did were so revolting, our volunteers complained so
bitterly of the smell and the taste that this was not pursued. In 1955, Mr Lazell,
obviously affected by the numbers of the new antibiotics that were appearing on the
scene, considered that if we were to go anywhere in this business we had to be in the
antibiotic field. The senior consultant to the company at that time was Sir Charles
Dodds.99 After a discussion with Mr Lazell, Sir Charles suggested that he should go
and talk to Ernst Chain, who was in Rome at that time. Mr Lazell sent his number
two, Mr McGeorge, to Rome to talk to Professor (later Sir Ernst) Chain. 
Chain’s first love was always penicillin100 and he suggested we should go back to
penicillin. He suggested that we should make para-aminobenzyl penicillin and
chemically modify it. It’s got an amino group, one can do all sorts of things with
amino groups if you are a chemist and we did have some quite good chemists. We
had no facilities at all for producing para-aminobenzyl penicillin, since at that time we
97 Professor David Greenwood wrote: ‘A standard strain of Mycobacterium tuberculosis often used in antibiotic
susceptibility testing as a control’. Letter to Mrs Lois Reynolds, 16 October 1998.
98 British anti-Lewisite (dimercaprol) – an antidote to lewisite, an arsenical war gas, which caused blistering, used
in World War II, with a disagreeable odour typical of mercaptans. A collection of papers, Sir R A Peters and British
anti-Lewisite, CMAC/GC/197, is held in the Contemporary Medical Archives Centre of the Wellcome Library.
See also Peters R A, Stocken L A, Thompson R H S. (1945) British anti-Lewisite (BAL). Nature 156: 616–619.
99 Sir Charles Dodds Bt FRS (1899–1973), medical biochemist, first isolated diethylstilboestrol, a synthetic
oestrogen, in 1938. See Dickens F. (1975) Edward Charles Dodds. Biographical Memoirs of Fellows of the Royal
Society 21: 227–267.
100 Abraham E. (1983) Ernst Boris Chain. Bi o g raphical Memoirs of Fe l l ows of the Royal Society 2 9: 43–91. A collection
of his papers, CMAC/PP/EBC, is held in the Contemporary Medical Arc h i ves Centre of the Wellcome Library.
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had no fermentation pilot plant and no fermentation facilities. There was no factory
and Beecham was virtually non-existent in the prescription medicine field. The 
first thing to do was to send appropriate colleagues to Rome. One of them is 
here, Ralph Batchelor; the other, Dr Rolinson,101 is not unfortunately. Using Chain’s
pilot plant, they produced quantities of para-aminobenzyl penicillin. These were sent
back to Brockham Park and my colleague, Dr Nayler,102 who unfortunately died a 
few years ago, was put in charge of a small group of chemists working with 
para-aminobenzyl penicillin. The obvious thing to do, using Schotten–Baumann
techniques,103 under mild conditions, to acylate it with all sorts of things. This we did
for most of 1956 and the early part of 1957. 
At the same time we thought it might be useful to make other possibly modifiable
benzylpenicillins, such as benzylpenicillins with a methylamino group, hydroxy
group, carboxy group, or whatever, on the benzene ring. During the course of that
work it was noted by Ralph Batchelor that the assays were throwing up funny
results.104 The microbiological assay was giving a figure of ‘x’, the chemical assay was
giving a figure of ‘2x’. Now my early training was as an analyst and I didn’t like this.
It seemed wrong. We thought about it and obviously there were a number of
possibilities. It could have been a weakly active penicillin, something like
methylpenicillin. After all, a culture medium has plenty of acetate and propionate
floating around, and there’s no reason why it shouldn’t have incorporated those. One
suggestion I made, and perhaps it was a good thing that I was totally ignorant of the
biochemistry, was that maybe the mould had been trying to make penicillin, but can’t
make it all, it can only make the nucleus. It has all the necessary bits and pieces to
make the nucleus – the valine, cysteine, etc. – without putting on side chains. That
was just out of the blue. Could it be that? We thought about it and both my colleague,
John Nayler, and I said, ‘Well it’s simple, all you have to do is add a bit of
phenylacetylchloride to the brew to make some penicillin-G and the assay should
101 Dr George Rolinson (b. 1926) was Associate Director of Research and Senior Microbiologist at Beecham
Pharmaceuticals at Brockham Park, Betchworth, Surrey, from 1955 to 1988. See Rolinson G N. (1998) Historical
Perspective: Forty years of b -lactam research. Journal of Antimicrobial Chemotherapy 41: 589–603. Dr Rolinson 
was unable to attend the Witness Seminar, but has seen and commented on the transcript as indicated in the
relevant footnotes.
102 Dr John Nayler FRSC (1927–1993) joined the newly formed Chemistry Department at Beecham Research
Laboratories in 1948, and was Head of the Department of Organic Chemistry there from c. 1960 to 1989. Nayler
and his colleagues’ demonstration of the existence of the penicillin nucleus (6-aminopenicillanic acid) in certain
penicillin fermentation solutions led to the synthesis of most of the commercially and clinically important
semisynthetic penicillins marketed by Beecham from 1959 to 1972. Nayler’s name appears on the majority of the
many patents and publications during this period. From Doyle P. (1993) John Nayler, 1927–93. Chemistry in
Britain 29: 531. See also Nature (1959), op. cit. note 88 above.
103 Dr Peter Doyle wrote: ‘The Schotten–Baumann method of acylation was originally developed some 120 years
ago for the synthesis of esters by the reaction of acid chlorides with alcohols under alkaline conditions. It was later
applied to the synthesis of amides by the reaction of acid chlorides with amines. The method is exemplified in most
textbooks of practical organic chemistry.’ Letter to Mrs Lois Reynolds, 5 April 1999. 
104 Dr George Rolinson wrote: ‘This is not quite correct. The discrepancy between the two assays was noted much
earlier by Rolinson and Batchelor, right at the beginning of the work on p-aminobenzyl penicillin in 1956.’ Letter
to Mrs Lois Reynolds, 8 June 1999. See also note 101 above, page 590. 
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agree’ and that’s what happened. We talked about it on the Monday, by the Thursday
we had shown that in that culture medium there was something that was probably 6-
APA as we now know it. Later on Ralph Batchelor showed more elegantly, using paper
chromatography, that you could show the same thing. That was in May 1957. It took
us something like six months to see solid 6-APA.105
Meantime in the chemistry labs, we we re working with more and more concentrated
solutions. Various extraction methods we re giving us material we could work with. We
did not see cry s t a l l i zed 6-APA until later that ye a r, perhaps early the following ye a r. By
using simple Schotten–Ba u m a n n - b u f f e red reactions we we re able to acylate this 
6 - A PA. That went on for some time, all of 1957 and 1958, it was even better when we
got the crystalline material, but during the course of that work we came across a
number of different pro p e rties. One was ve ry interesting. As soon as a sterically-
h i n d e red side chain was introduced into a penicillin nucleus, you got resistance to some
b -lactamases. That was the first clue and it was fairly obvious to continue with that. 
At this stage I must pay a tribute to the late Dr Na y l e r’s contribution.1 0 6 It was Dr Na y l e r
who was in charge of the chemistry group and it was mainly his ideas that led to
methicillin, to isox a zole penicillins, ampicillin, and later on to amox ycillin, carbenicillin,
and most of the other penicillins that we eventually produced. It was his contribution to
the chemistry that we have much to be indebted to. We published the work, the initial
d i s c ove ry of 6-APA in Ja n u a ry of 1959 and then of course the roof fell in because we
we re approached by practically eve ry pharmaceutical company in the world. Be e c h a m
had nothing, we had no antibiotic factory, we had a small microbiology pilot plant, we
had a chemical pilot plant in Brockham Pa rk, we had no sales organization, we had just
nothing. Eve rything had to be created from 1959 onwards. To do that Be e c h a m
o bviously had to tie up with other companies. I was made Di rector of Re s e a rch in 1963,
and all this was happening about this time. The company decided to tie up with the
Bristol Laboratories in the States and the quid pro quo was ve ry simple, they we re going
to help us into the penicillin-G business. They we re going to supervise the building of
our factory at Wo rthing, which they did, and supplied us with strains of organism to
p roduce the penicillin-G. By late 1959, I think it was, I was called in to see the De p u t y
Chairman. He had had an approach from the Ba yer company who had found a way of
splitting the side chains from penicillin-G, obviously a much more efficient way of
p roducing 6-APA than trying to brew the thing in culture without any side chain.
Obviously then the company had to tie up with Ba yer again on a quid pro quo basis and
105 Dr Peter Doyle wrote: ‘I have no doubt that Drs Rolinson and Batchelor were aware of this assay discrepancy
while working in Rome with Professor Chain during 1956. However, they certainly did not communicate this
problem to myself or Dr Nayler nor as far as I am aware to Professor Chain nor to Dr Farquharson, then Director
of Research at Brockham Park. The discrepancy was in fact well known to other workers in the field, particularly
in several USA companies, notably Eli Lilly, Pfizer, and Bristol Labs. The speculation that it might be due to the
presence of a penicillin without a side chain had also occurred to Japanese workers. However, no-one previous to
Dr Nayler and I had thought of proving it by acylating the mixture in situ to convert the biological inactive
penicillin nucleus to produce biologically active material. It is interesting to speculate that if Dr Nayler and I had
been aware of these assay differences earlier, Beecham might have made the discovery of 6-aminopenicillanic acid
at a much earlier date than May 1957.’ Letter to Mrs Lois Reynolds, 27 October 1999.
106 op. cit. note 102 above.
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they supplied us with information about their process which was worked on by my ow n
colleagues at Bro c k h a m .1 0 7 By the beginning of 1960 we had the process of pro d u c i n g
large quantities of 6-APA, we had the clues that had already led us into what to do with
it when we got it, and the whole story went on from there. I don’t think there’s much
m o re I want to say. I should mention, of course, that apart from Sir Ernst Chain and Si r
Charles Dodds, who we re our two senior consultants, Sir Ian He i l b ron and Professor A
H Cook at Imperial College we re also our consultants. Later on many other scientists
came into the picture, for instance Dr St ew a rt who’s sitting at the back there, so we had
the benefit of a lot of advice and for which we we re ve ry grateful.
Batchelor: If I can pick up some other points outside the ones that Peter Doyle has
made. It’s perhaps worth reminding everyone that after penicillin-G and the
recognition that by adding a precursor to the fermentation you could get other
penicillins, Otto Behrens and his co-workers at Eli Lilly made many such penicillins
and published their work in 1948.108 Penicillin-V was actually one of the penicillins
they made in this way but they didn’t recognize its special properties. It wasn’t until
Brandl and Margreiter in 1954 that the acid stability and oral absorption of penicillin-
V was recognized. There had been some chemical modification of penicillin-X, 
p-hydroxybenzyl penicillin by Coghill and his group, which had been published in
1949.109 This was essentially the situation when we at Beecham came into the picture. 
When I first got involved and went to work in Rome, I didn’t even know the structure
of penicillin or have any other preconceptions about the substance, which as it turned
out, was probably a good thing. 
People ask what part did Sir Ernst Chain play?110 I think one of the essential things he
provided was the environment for us to work in and he convinced the company we
should be allowed to do certain work. Without him I think we would never have
discovered 6-APA and developed the semisynthetic penicillins. Another thing about
Chain was his enormous enthusiasm – if you weren’t enthusiastic, you didn’t work
with him for long. That, I believe, was another important contribution. 
What I do remember clearly was the discrepancy111 in the antibiotic assays? We were
107 Dr George Rolinson wrote: ‘Perhaps it could be mentioned that enzymatic splitting of a penicillin to produce
6-APA was first achieved in our own laboratories (Beecham Research). The Beecham patent for this process was
filed in March 1959; the patent for the Bayer process was not filed until September 1959.’ Letter to Mrs Lois
Reynolds, 8 June 1999. See also note 101 above, page 591. 
108 Be h rens O K, Corse J, Ed w a rds J P, Garrison L L, Jones R G, Soper Q F, Van Abeele F R, Whitehead C W. (1948)
Biosynthesis of penicillins. IV. New crystalline biosynthetic penicillins. Jo u rnal of Biological Chemistry 1 7 5: 793–809. 
109 Brandl E, Ma r g reiter H. (1954) Ein saurestabiles biosynthetisches Penicillin. Ö s t e r reichische Chemiker-Zeitung 5 5:
11–21. Coghill R D, Stodola R H, Wachtel J L. (1949) Chemical modifications of natural penicillins. In Clarke H
T, Johnson J R, Robinson R. (eds) The Chemistry of Pe n i c i l l i n . Princeton, NJ: Princeton Un i versity Press, 680–687.
110 See Chain’s biographical note 5 above.
111 Dr George Rolinson wrote: ‘I introduced the chemical assay myself right at the beginning of our work on p-aminobenzyl
penicillin, for the reasons given in my article (Rolinson 1998, op. cit. note 101 above, page 590) and the discre p a n c y
b e t ween the chemical and the microbiological assay was clearly apparent in the ve ry earliest fermentation studies long
b e f o re we began the work on the isolation of p-aminobenzyl penicillin.’ Letter to Mrs Lois Reynolds, 8 June 19 9 9 .
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making p-aminobenzyl penicillin to ship back to the chemists in England, and the
discrepancy was noticed because I was very impatient, wanting rapid assay results in
order to isolate and purify the material. The bioassay was too slow and so I used a
chemical one. It was then we became aware of the discrepancy but kept very quiet
about it while still in Rome, obviously for very good industrial and commercial
reasons. If we then go on from the initial experiments to which Peter [Doyle] referred,
that is acylating some no-precursor broth with phenylacetylchloride and showing that
penicillin-G was formed. I can clearly remember taking the chromatograms which
had been placed on agar seeded with Bacillus subtilis to reveal the presence of any
antibiotics, out of the incubator. I thought at the time it had been a very nice
experiment with a good clear-cut positive result. I don’t believe, however, that there
was any great optimism that we might finish up with some useful products or so 
many useful semisynthetic penicillins. We had already made many derivatives from 
p-aminobenzyl penicillin, none of which were of any interest. My own personal view
is that we really had no conception of what it was going to lead to.112
It’s worth reminding people that the amount of 6-APA we were dealing with in the
fermentation was at the most 0.1 mg/ml and usually rather less. One of the reasons
for this low concentration we now know to be because 6-APA reacts very rapidly with
carbon dioxide leading to a stable degradation product which Marvin Johnson at
Wisconsin identified as his factor VI in his early studies with radioactive tracer studies.
This, of course, limits the amount that can be made by fermentation.
There were other limitations imposed by this low concentration of 6-APA, which was
responsible for isolation and crystallizing. Peter [Doyle] mentioned the enzymic
reactions. Not only was it difficult to recover and purify but we also needed dry, solid
6-APA for some of the chemical reactions needed to make important semisynthetic
penicillins – methicillin, for example.
We did look for an organism to remove the side chain and found a penicillin acylase
in a Streptomyces spp., which was unfortunately both exocellular and penicillin-V
specific. However, it did provide a route to 6-APA from which many of the early
laboratory samples of semisynthetic penicillins were made.
It was interesting, as Peter [Doyle] mentioned, that Bayer came on the scene with a
bacterial culture which was very good at splitting penicillin-G. We then picked this
up and developed it on a large scale and it was only a very short time before we were
visiting Bayer and putting our own bacterial process, which was a modification of
theirs, into production in their factory in Germany.
The situation in the 1950s is interesting, and I think answers one of the questions
raised earlier as to whether resistance due to penicillinase (now b -lactamase) was
recognized as a problem. I think the answer is that we at Beecham certainly did. When
Bristol-Myers became invo l ved with Beecham their interest was commercially orientated
to getting a ‘n ew penicillin’ to the market as quickly as possible, which was why
112 For a contemporary view of the developments between 1956 and 1961 written by another observer, see note
100 above, pages 63–65. 
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phenethicillin (Broxil: Beecham) was the first semisynthetic penicillin to be launched.
To those of us at Beecham the slightly later methicillin was the jewel in the crown,113
because it solved the problem of penicillin-resistant staphylococci, at that time
responsible for the closing of many hospital wards. This was when we came to feel we
had achieved something worthwhile.
I won’t go into any more detail on this, except to say that it is worth noting that this
one piece of work led to almost 30 semisynthetic penicillins becoming available to
medicine with different uses, ranging from phenethicillin through methicillin, the
isoxazoles, ampicillin, amoxycillin, carbenicillin and even the lactamase inhibitors,
sulbactam and tazobactam.114
It’s interesting that just after the publication of the isolation of 6-APA, the British
Medical Journal carried an editorial on 14 March [1959], which said it was very
uncertain about the value of 6-APA and to what it was going to lead.115 In this context
I should just point out that today some 11 000 tonnes of 6-APA is made every year,
which among other things is used to make 6500 tonnes of ampicillin, and over 10 000
tonnes of amoxycillin. It’s not the first time the British Medical Journal has got it
wrong, but by the time of the publication of 6-APA those of us at Beecham were
already seeing useful compounds in the pipeline.
The total tonnage of semisynthetic penicillin today is in excess of 18 000 tonnes –
interesting when we consider the total for cephalosporins, which we shall be talking
about later, is only some 5500. Perhaps I should stop at that point and let other people
say a few things.
Booth: A thing I would ask is you talk about bringing these things on the market. This
was before the establishment of the Committee on Safety of Drugs and so on.116 How
did you get your stuff onto the market? Did you just advertise it and let the doctors
prescribe it?
Doyle: Methicillin was an interesting case. We actually made methicillin in the lab I
think it was the May of 1959, and it was on the market in the September of the
113 Methicillin, or sodium 6-(2,6-dimethoxybenzamido)-penicillate monohydrate, was first known in Beecham
Laboratories as BRL 1241, given the trade name of Celbenin. It was discontinued in 1993. op. cit. notes 121 and
169 below. Professor David Greenwood wrote: ‘Incidentally, the trade name, Celbenin, was formed from the name
of C E L Bencard, who was, I think, the Managing Director of the Beecham-associate firm, Bencard, who used to
market methicillin and the oral antistaphylococcal penicillin, cloxacillin (Orbenin).’ E-mail to Mrs Lois Reynolds,
5 November 1999.
114 See Rolinson (1998), op. cit. note 101 above.
115 Anon. (1959) The penicillin nucleus. British Medical Jo u rn a l i: 701–702. Professor David Greenwood wrote: ‘T h i s
B M J editorial was later re vealed to have been written by Professor L P Ga r rod. See Wa t e rw o rth P M (ed.) (1985) L
P Ga r rod on antibiotics – a selection of his British Medical Jo u rn a l editorials. Jo u rnal of An t i m i c robial Chemothera py
1 5 ( Suppl. B): 1–46. The editorial cited is re p roduced on pages 32–33.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999.
116 See Tansey E M, Reynolds L A. (1997) The Committee on Safety of Drugs. In Tansey E M, Catterall P P,
Christie D A, Willhoft S V, Reynolds L A. (eds) Wellcome Witnesses to Twentieth Century Medicine, vol. 1. London:
The Wellcome Trust, 103–132.
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following year and being prescribed. It took about 18 months, a bit less than 18
months. Now as you say, that was before the Dunlop Committee, it was before the
Committee on the Safety of Medicines, before thalidomide, I think we did two weeks
of toxicity studies. It was very minimal.
Booth: Could you do that now?
Doyle: No, of course you can’t. Today, it would take between eight to ten years.
Booth: Which increases the cost enormously.
Dr Geoffrey Asherson:117 Sheehan makes a great point about patents in this area.118
Was this work in general protected by a patent? Or was it your knowledge of your
process, which rival firms did not have, that enabled you to produce semisynthetic
penicillins to advantage?
Doyle: The patent situation was interesting. We were able to take out a patent for
crystalline 6-APA which we published all over the world and of course all the materials
from it, methicillin, etc. We had a general patent on acylation and then specific
patents covering everything that we could think of. So everyone that marketed those
products had to pay a royalty. Now synthesis routes were a bit complicated, because
Professor Sheehan, as you probably know, had done a lot of work on the synthesis of
penicillin-V. He published something like seven papers I think, and in one of the Ciba
Foundation symposia he contended that 6-APA would be unstable and couldn’t
exist.119 Later on he claimed that he had made 6-APA by his synthetic route and I think
he got a patent in the USA for that. I believe that Bristol Laboratories had to pay him
a royalty on their marketing of our penicillins, which I thought was a bit puzzling. We
got involved in tremendous patents arguments in the United States and on top of that
there was an anti-Trust action as well, so it all got rather involved.120 An extremely
good chemist that I had working with me at the time repeated Sheehan’s work. He
117 Dr Ge o f f rey Asherson (b. 1929) was Head of the Division of Immunological Medicine at the Clinical Re s e a rc h
C e n t re, No rthwick Pa rk Hospital, Ha r row, from 1970 to 1995. He was interested in patients who failed to make
antibodies and in the control of the immune re s p o n s e .
118 Dr Ge o f f rey Asherson wrote: ‘John C Sheehan was the first to pre p a re a fully synthetic penicillin. [In his book] he show s
the American side of the story of the semisynthetic penicillins and devotes a lot of space to rival patent claims in which
John Peter Clayton and J H C Na y l e r, then of Be e c h a m’s, played an important role. He notes that Beecham “became
i n t e rested in the penicillin field at just about the time I was finishing my penicillin synthesis”at MIT. Beecham and the
American company, Bristol, agreed to join in a ve n t u re producing synthetic and semisynthetic penicillins. T h e re was
argument over patents between Sheehan and Be e c h a m’s which invo l ved processes for preparing and acylating free APA. Pa rt
of the argument was that the Sheehan disclosure was "insufficient ...to enable one of ord i n a ry skill in the art to follow the
d i s c l o s u re and produce what Sheehan alleges he obtained".’ Letter to Mrs Lois Reynolds, 18 Ja n u a ry 1999. See Sheehan J
C. (1982) The Enchanted Ring: The untold story of penicillin. Cambridge, MA: MIT Press. Quotes above on pages 160, 185.
119 Wolstenholme G E W, O’Connor C M. (eds) (1958) Ciba Foundation Symposium on Amino Acids and Peptides
with Antimetabolic Activity. London: J & A Churchill Ltd, 257–258.
120 See Federal Trade Commission. (1958) Economic Report on Antibiotics Manufacture. Washington, DC:
Government Printing Office. We thank Dr Alan Yoshioka for drawing our attention to this reference.
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tried to repeat it twice, but could not repeat Sheehan’s claim to the synthesis of 6-APA.
I think that is all I need to say.
Stewart: This is a marvellous, modest account by Peter Doyle and Ralph Batchelor of
what was a remarkable series of observations. Although they say that some of it was
accidental, a great deal was well planned with astonishing speed. From the time that
I first received methicillin, it was like penicillin-G all over again. We were able to see,
without the possibility of a balanced trial, that there were cases who were then so ill
with penicillinase-forming, highly-resistant staphylococci that one simply had to take
a chance. The first cases of septicaemia, osteomyelitis and so on, had to be treated on
that basis in 1959, and include some that were treated by Dr Trafford and Dr
Douthwaite.121 This made it quite clear that these drugs had a most unusual level of
activity as indeed ampicillin and some of the other semisynthetics had later.
I should comment on Peter Doyle’s reference to John Sheehan at MIT. There was a
competitive enterprise operating in the USA. The waters are quite murky in some
ways at that period, and they were claiming to have isolated 6-APA, or even to have
synthesized it. But the practical point was that despite all the talk about this, the only
way to do it commercially was the way the Beecham Group did it, and, considering
the modest facilities that were described, in a remarkably ingenious fashion very
quickly. This opened the door to all kinds of things. It wasn’t just a therapeutic
advance. It was perhaps the first step forward in strategic biochemical chemotherapy,
because we began to understand from this work how it was that certain functional
groups could be introduced and would make an enormous difference to spectrum, to
allergy, to all kinds of things.
Tyrrell: I’d like just to tell you about a side issue which illustrates what’s been said
before on the tremendous enthusiasm of Ernst Chain and his belief that penicillin
would be the source of all the very best future antibiotics. He was sure that it would
also be the source of the best antivirals. He built partly on the work that Shope122 had
done, showing that from fungal cultures you could extract an antiviral substance,
which cured mice with the lethal virus infections. To cut a long story short, through
work at Merck and elsewhere, it turned out that these fungi were carrying double-
stranded-RNA-containing fungal viruses and if you extracted the double-stranded
RNA then that would act as an antiviral agent by inducing interferon. It worked
beautifully in mice. And Chain was so persuasive that he got Beecham to do a lot of
121 Douthwaite A H, Trafford J A R. (1960) A new synthetic penicillin. British Medical Journal ii: 687–690.  This
is the first reported controlled trial of BRL 1241, Celbenin.
122 Richard Edwin Shope (1902–1966) was an American pathologist and virologist, then at the Department of
Animal and Plant Pathology of the Rockefeller Institute for Medical Research, Princeton, New Jersey, and the
Merck Institute for Therapeutic Research, Rahway, New Jersey. Professor David Greenwood wrote: ‘Shope isolated
the antiviral from a fungus growing on the “isinglass cover of a photograph of my wife, Helen, on Guam, near the
end of the war in 1945”. He named the substance ‘helenine’ – “largely out of recognition of the good taste shown
by the mold ...in locating on the picture of my wife”.’ Letter to Mrs Lois Reynolds, 16 October 1998. See also
Shope R E. (1953) An antiviral substance from Penicillium funiculosum. Journal of Experimental Medicine 97:
601–650, quotes on pages 601, 614–615.
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the development work and while Merck we re making synthetic poly-IC pre p a r a t i o n s ,
he produced biologically produced double-stranded RNA, which protected mice but
was too toxic to use in man.
Dr Martin Cole:123 Ralph [Batchelor] referred to splitting penicillin-V, and I was
rather interested in this as a microbiologist and a biochemist. At that time there was
a lot of work going on on the microbiological transformation of all sorts of drugs and
we wondered whether it might be possible to do microbiological transformation on 
6-APA. Hydroxylation of one of the methyl groups would be an example. We started
having a look at 6-APA and thought we’ll have a protected form of it as well, that is
protection on the amino group, for which we’ll use benzylpenicillin. We decided to
look at some bacteria which we already had in the laboratory; they were in the
bacteriologist’s culture collection. Within a week or two of starting these experiments
we found a strain of Escherichia coli which would readily cleave the side chain in
penicillin-G. As Peter Doyle said, the Bayer company in Germany discovered a similar
thing, and they pipped us to the post on the patent, but I want to illustrate how facile
that reaction was. I looked back through my notes and saw that one of these strains
of E. coli came from Eleanor’s [one of the laboratory’s technicians] rainwater butt, this
was just an environmental strain of E. coli. We grew the organism up and I think
Ralph Batchelor carried out the reaction. If you collected the cells and suspended
them in a 2 per cent penicillin-G solution, they would split that penicillin-G to 6-
APA, 95 per cent yield in four hours. Once we had done that, I think it is true to say,
Ralph, it had a dramatic effect on the availability of 6-APA. Yes, it’s true as Peter says,
we couldn’t scale these things up readily, we didn’t have the facilities, we looked to
others to do this. I don’t know whether either of you [Doyle or Batchelor] can confirm
this, but I do remember those who were designing our factory at Worthing were very
unhappy about the idea of having to change the design from a direct 6-APA
fermentation process using Penicillium chrysogenum, to having to have a double
fermentation process, one to make penicillin-G and then another to grow up the
E.coli to knock off the side chain to make the 6-APA, but maybe they would like to
comment on that?
Batchelor: That’s absolutely right, what Martin says. Eleanor was actually one of the
technicians in the lab and it was her water butt that it came from, but what is
interesting is that we worked very quickly, within five months. It was the week before
Christmas that that reaction was spotted, and by May the next year we had made
enough 6-APA to be ready for the marketing of methicillin. Without that material, we
wouldn’t have been able to market methicillin at the time, and I remember when we
first ran the pilot plant production with this and I was there directing operations and
even had my boss working for me at the time, turning knobs and controlling pH. We
123 Dr Martin Cole (b. 1933) joined the Department of Microbiology, headed by Dr G N Rolinson, at Beecham
Research Laboratories at Brockham Park, Betchworth, Surrey, in 1958. He became Head of the Biochemical
Services Department and then Research Coordinator, until 1990. See Cole M. (1980) ‘ b -Lactams’ as b-lactamase
inhibitors. Philosophical Transactions of the Royal Society of London B 289: 207–223.
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finished up, as one of the shift workers said, ‘We had more 6-APA in our fingernails
at the end of the reaction, than we normally made in a week’s production’ and I was
collecting the E. coli cells in a Sharples super centrifuge. Health and Safety at Work
Regulations didn’t exist in those days, and the easiest way to get it out was to put one’s
hand down the tube of the Sharples and get up the E. coli sludge. What’s interesting,
of course too, are the things that 6-APA has led to, and it’s a pity that Malcolm Lilly 124
is not here, but of course with his collaboration Beecham devolved an immobilized
enzyme system for this, which I think was probably the first commercial immobilized
enzyme used on a large scale, and all of that 6-APA that I was talking about is now
made all over the world using immobilized enzyme technology and very efficiently.
From the floor: His pilot plant is in the Science Museum on display.
Booth: I wonder if I could ask the clinicians present to talk about the impact of these.
What I remember so well of that period is being able to give penicillin by mouth. This
was a fantastic change from having to give injections, particularly to children.
Stewart: This of course was the substitution of the a-carbon atom which conferred
acid stability. It had been apparent before, but this was what made such an enormous
difference in treating children with the semisynthetic penicillins generally. There were
two advantages for the price of one, because along with those substituents there were
also possibilities of hindering, if that is the word, the attachment of b -lactamase to
penicillin. In terms of the structure–activity relationship, this was an enormous
breakthrough. But clinically, the other point was that, although not to quite the same
extent, the new derivatives lacked the toxicity of penicillin-G, being substances which
reacted on muramic acid in cell walls.125 Since there is no counterpart in mammalian
cells, these penicillins were virtually non-toxic, quite unlike almost all the other
antibiotics, though subject a year later to a totally different chain of resistance patterns
in previously sensitive bacteria.
Batchelor: I think it’s interesting to realize that those of us involved certainly thought
that methicillin was a good compound, although we would have liked one a bit more
active, and quickly found one. My own memory is that of course we had the mixture
of isomers of ampicillin, before we had the D(–) form which effectively doubled the
activity. I still believed then that many of us felt that if it perhaps was an interesting
124 Professor Malcolm Lilly FRS (1936–1998) was the first British Professor of Biochemical Engineering at
University College London, from 1979 until his death in 1998. He was unable to attend the Witness Seminar and
sent a three-page contribution, which was circulated at the meeting. ‘...In 1964 I decided that one of the enzymes
I wanted to work on was penicillin acylase (or penicillin amidase) which was the enzyme which was able to remove
the side chain from benzyl penicillin and which Beecham’s routinely grew in very large fermenters. They would
then use the whole microorganism to carry out the conversion of benzyl penicillin to 6-aminopenicillanic acid as
a single batch process...’. Letter to Dr Tilli Tansey, 12 May 1998. The full text will be deposited with the tapes,
correspondence and other documentation from the Witness Seminar in the Contemporary Medical Archives
Centre of the Wellcome Library.
125 For a description of the characteristics of muramic acid, see note 10 above, pages 89, 92–93.
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compound, and we would have liked it to have been more active. I think it was ve ry
much marketing pre s s u re from Bob Wilkins that pushed ampicillin along the road and
it is interesting to consider how much marketing has affected things around the world.
This is perhaps not the place to talk about it, but it’s interesting to look at dosages
a round the world, and what is the right dosage in one country isn’t the right dosage in
a n o t h e r.1 2 6 Clinical practice is quite different. It’s interesting to think that when I gave
you those figures for semisynthetic uses, China has virtually no semisynthetic penicillin
usage, just a little ampicillin sodium by injection, even though it’s the largest pro d u c e r
of penicillin-G. T h e re’s no ampicillin or amox ycillin orally really to speak of at all. So it’s
i n t e resting to think about that when we come to talk about resistance later on today. Bu t
I think there’s certainly an effect of marketing on what has happened with these things. 
Booth: Doctors are very gullible aren’t they?
Batchelor: They are not only very gullible. We heard earlier that they are very
conservative, and I can remember how difficult it was to convince them that you
could use amoxycillin three times a day because they all wanted to stick to four times
a day and in some countries it is actually used as infrequently as twice a day.
Booth: Now there must be somebody here from the clinical side who has some
comment to make on that. I am just intrigued to know that at that stage marketing
was a crucial thing and it must be what determined what practice was in the hospital.
There was no accepted practice or was there? There were no infection committees in
those days or were there?
Batchelor: Can I just add one other thing? One of the things that was always said 
was the desire to have a narrow-spectrum antibiotic, a rifle rather than a shotgun. It’s
i n t e resting to consider that we did develop something like a rifle for the 
gram-negatives, temocillin, which was singularly unsuccessful in the market place 
and maybe the medical profession say they want a rifle, but they prefer the 
broad spectrum.
Booth: I do remember at Hammersmith certainly that our late-lamented friend, Mary
Barber,127 was very much involved in guidance over antibiotic usage through the 1960s
until her unfortunate death. I think she must have died in 1965. But what was the
position when she was there? Did she run a policy on antibiotics? Pa m e l a
[Waterworth], can you answer that? Did she run a policy for the clinicians on the use
of antibiotics? Was advice given?
Waterworth: Oh yes, extensively. Graham Ayliffe should answer that. He was
working with her then.
126 Dr Batchelor wrote: ‘Generally the UK and USA work to a minimum effective dose while Germany would
recommend a maximum tolerated dose.’ Letter to Mrs Lois Reynolds, 24 March 1999.
127 See biographical note 9 above.
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Ayliffe:128 Yes, I think we are now going into the problems of resistance at this stage,
but in about 1957 Mary Barber was perhaps the first person in the country to
introduce an antibiotic policy for most of the hospital [Hammersmith]. In this policy
she reduced or tried to eliminate the use of penicillin apart from a few conditions such
as endocarditis, to reduce the use of antibiotics as much as possible, and to give all
antibiotics in combination. This was actually followed by a reduction in the numbers
of penicillin-resistant strains of Staphylococcus aureus isolated.  She mainly used
erythromycin and novobiocin as a combination therapy, and resistance didn’t emerge
for a while, but gradually, over the years, it did. When methicillin appeared this policy
was no longer needed. But she still had a written policy which she enforced with a
hand of iron in Hammersmith Hospital as long as she was there.129
Dr Tilli Tansey:130 Did she develop that because of her concern about resistance? And
were other people influenced by her decision, or was she alone in doing this?131
Ay l i f fe : No, I think there we re a number of others who we re also worried about re s i s t a n c e
at that time. In part i c u l a r, Ed w a rd Low b u ry was working on burns patients in Bi r m i n g h a m.1 3 2
He found in the 1950s that resistance emerged rapidly to tetracyc l i n e , e ry t h ro m ycin and
n ovobiocin and there was really little else left at that time for tre a t i n g s y s t e m i c
staphylococcal infections.1 3 3 The use of combinations only delayed the onset of re s i s t a n c e .
B o o t h : I think so far as individual clinicians we re concerned, and Ma ry Ba r b e r, there was
little doubt that you did what you we re told or else. She was a ve ry persuasive person.
Tyrrell: The Northwick Park Hospital was being designed about the time these things
were going on and there were two other things which were mentioned and thought
128 See biographical note 84 above.
129 Professor Go rdon St ew a rt wrote: ‘In re t rospect, and with all respect to Ma ry Ba r b e r, I would like to make the point
that, despite fre ewheeling, there was always an antibiotic policy with penicillin from 1944 onwards in the UK. This was
p a rtly because of shortage, but also because it soon became apparent that staphylococci, coliforms and gonococci became
resistant to alternative drugs. The problem became acute in 1954 in many major clinical centres internationally. The use
of antituberculous drugs from 1952 onwards was also strategic.’ Letter to Mrs Lois Reynolds, 14 October 1998.
130 Dr Tilli Tansey is Convenor of the History of Twentieth Century Medicine Group and Historian of Modern
Medical Science, Wellcome Institute for the History of Medicine, The Wellcome Trust.
131 Miss Pamela Wa t e rw o rth wrote: ‘I think that Professor L P Ga r rod was the first to try to pre vent resistance deve l o p i n g ,
by limiting the use of new drugs when they first became available. He saw that the indiscriminate use of these, when
they we re introduced rapidly, led to untreatable infections so when the manufacturers brought him a new drug he put
p re s s u re on them not to push its use, but to hold it in re s e rve for genuine emergencies. When the next antibiotic arrive d
the last was released. This continued until methicillin arose, and was undoubtedly the main reason why resistance rates
in this country we re, at that time, lower than in most others.’ Letter to Mrs Lois Reynolds, 9 October 1998.
132 Professor E J L Lowbury (b. 1913) was Head of Bacteriology at the Medical Research Council Industrial Injuries
and Burns Unit at the Birmingham Accident Hospital from 1949 to 1979; Honorary Director of the Hospital’s
Infection Research Laboratory from 1964 to 1979; and Honorary Professor of Medical Microbiology at the
University of Aston from 1979. He was unable to attend the Witness Seminar and sent reminiscences to Dr Tilli
Tansey, dated 14 April 1998, which will be deposited with the tapes, correspondence and other documentation
from the Witness Seminar in the Contemporary Medical Archives Centre of the Wellcome Library.
133 L ow b u ry E J L, Topley E, Hood A M. (1952) Chemotherapy for Staphylococcus aure u s in burns. L a n c e t i: 1036–1042. 
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about, but some of them never eventuated. One was the importance of isolation of
people who are producing and shedding organisms which are resistant. We were in
favour of having isolation rooms in the hospital, but this was very unfashionable and
thought to be retrograde. The days when you had to worry about infection were in
the past and not something which the 1970s hospital needed to concern itself with!
Another thing which I remember discussing with Robert Blowers 134 was to try and get
someone to study, in a rigorous way, the effects of different concentrations and
durations of antibiotic treatment. I don’t think anybody ever took that very seriously,
but the point was that we felt that prolonged treatment was likely to induce prolonged
selection of drug-resistant organisms, and that often the standard durations of
treatment were rather pulled out of the hat, or were the ones that had been used for
the last drug. They weren’t actually ascertained by careful study of the patients – and
I think that’s a message for the present as well.
Lambert: Just to back up David Tyrrell on that point, I think there has been an 
extraordinary gap in this whole field. In the recent Select Committee of the House of
Lords on antibiotic resistance,135 one of the special points made was the extraordinary
ignorance about dosage duration and dose interval, in which there are quite superficial
leaps from bits of pharmacokinetics to clinical implications. After the initial trials
which get the drugs through the Committee of Safety on Medicines, these aspects are
never taken up again. It is still a very fundamental gap in our knowledge of how to
use these drugs. 
Mitchison: Can I make one comment about Mary Barber and her interest in
staphylococci, because I was trying to organize a record system using computers for
the first time. The reason for doing this was Mary wanted her records solely in terms
of staphylococcal infections, whereas the other clinicians and bacteriologists wanted
them in different forms. But it is true that there was this initial concentration on
staphylococci that later, of course, expanded to gram-negative organisms.
Dr Basil Bard: 136 I would like to make a point about [Ernst] Chain. He once said to
me that he would not have been able to do his work today because of the impurities
in his non-lethal drugs, but he insisted that no-one came to any harm over this.
Booth: Chain was a remarkable man and I remember his enthusiasm. He once took
me round his newly founded department at Imperial College after he came back from
134 Dr Robert Blowers FRCP FRCPath was Head of the Division of Hospital Infection and Microbiology at the
Clinical Research Centre at Northwick Park Hospital, Harrow.
135 op. cit. note 4 above.
136 Dr Basil Bard (b. 1914) was called to the Bar in 1939, joining the staff of the Coal Commission in 1940. During
the war he served with the Ministry of Supply from 1941 to 1943 and the Ministry of Aircraft Production from
1943 to 1945. In 1945 he joined the Confederation of British Industry, moving to the newly established National




Rome, and showed me six huge fermentation vats and said he was very proud that he
was the only professor of biochemistry in the country that had such a department. It
was based on what you had all been doing.
We are going to move on now firstly to cephalosporins, and resistance in bacteria.
Bugs come from all sorts of funny places. I remember when Rank Hovis McDougall
were trying to manufacture protein from a microorganism. They went all over the
world looking for a bug and finally found it in a small quarry just down the road from
the factory near Darlington. Cephalosporins don’t quite have that story, but there is
something of that in it and we were going to ask Dr Basil Bard, but he is going to ask
his son to speak for him. 
Bard: That’s correct. I am going to ask my son to deliver my script, as I am not able
to do so myself. I would just like to make a point that Austin Bide137 was the chap with
whom I had to negotiate at Glaxo, because he was in charge of the patents at that
time, and he eventually became Chairman, which was very considerate of him.
Prepared text read by Dr Basil Bard’s son, Nicholas Bard: I first came into contact
with the cephalosporins in 1953, when I was at NRDC. I had been invited to
Professor Florey’s laboratory at Oxford to check up why he had not received 25 grams
of cephalosporin-C: they should have been delivered to him from a Professor Brotzu138
in Sardinia, but appeared to have ‘not been received’. 
It was Professor Brotzu who had first discovered cephalosporins,139 in 1952; he found
that the technology was too difficult for him in Sardinia, and he passed it over to
Professor Florey at Oxford. Cephalosporin-C was a fraction of the result, the others
being penicillins,140 and so was really unknown. We circulated information to the
industry, and found that only Glaxo had the resources to develop and produce
cephalosporin-C; accordingly, we granted them a worldwide licence to do so.
Gl a xo insisted on doing this at their expense, although NRDC was quite willing to pay
the cost. The American firm Eli Lilly said that they wished to participate in the deve l o p m e n t
of cephalosporin-C, and we permitted them to do so, granting them a non-exc l u s i ve licence,
(a) which excluded the United Kingdom and other British and Commonwealth territories;
(b) on terms that they we re to hand over their results to Gl a xo, and license Gl a xo to utilize
those results. We described this as a ‘penicillin in re ve r s e’ agreement. 
137 Sir Austin Bide Kt FRSC (b. 1915), Honorary President of Glaxo Holdings plc since 1985, was unable to attend
the Witness Seminar.
138 Professor Guiseppe Brotzu isolated an aerobic mould from the sea, near a sewage outfall in Sardinia, which
eventually yielded cephalosporin. See Brotzu G. (1948) Ricerche su di un nuovo antibiotico. Lavori dell’ Instituto
d’Igiene di Cagliari, 1–11. 
139 Professor David Greenwood wrote: ‘Brotzu isolated the mould that was eventually shown to pro d u c e
cephalosporin-C in July 1945, as he makes clear in his original paper.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999.
140 Professor David Greenwood wrote: ‘Three components were eventually found to be present: cephalosporin-N,
a penicillin; cephalosporin-P, a steroid-like antibiotic; and cephalosporin-C, a minor component of the antibiotic
complex first detected by E P Abraham of Oxford.’ Letter to Mrs Lois Reynolds, 16 October 1998.
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A consequence of this was that Eli Lilly discove red a commercial route to
cephalosporanic acid: whereas Professor Abraham141 at Oxford had earlier identified
this material, and had discovered a theoretical route which only yielded 1 per cent
production, Eli Lilly’s route could achieve production of 80 per cent. Cephalosporanic
acid had two points where groups could be attached, and so it was possible to make
cephalosporins which were highly selective, e.g. for eyes, or for taking in materials
orally instead of by injection. 
In 1957, both Glaxo and Eli Lilly produced their materials for the market, cross-
licensing one another. We did not find that either the difficulties of licensing, or the
relatively unknown material, was viewed by the industry as inhibiting. We soon had,
in addition to the British and American licensees, a Swedish licensee and a Japanese
licensee, to whom we explained that they could evolve their own cephalosporin
product and secure patent rights on it, and need only pay us 4 per cent for the
privilege – although we charged progressively higher rates for the option and licence.
This work was supervised by Sir Howard Florey, Sir Robert Robinson142 and Sir
Charles Dodds.143
I always had confidence in the cephalosporins and felt sure that they would find their
place in medicine, because they were uniquely resistant to penicillinase. The
consequences of this project for NRDC and Oxford University were receipt, over the
years, of a wholly unprecedented £125 million in royalties, together with widespread
recognition for both these institutions and the principal individuals involved.
Booth: Well, that’s a very clear account. Thank you very much indeed, Dr Bard. I
wonder if Dr Stewart would like to carry on at this point. 
Stewart: The story of cephalosporins144 is in its way, I suppose, quite as interesting,
quite as complicated, and quite as romantic, as that of the penicillins. I have been
asked to talk about the cephalosporins and I am very glad to do so, but before
embarking on it I should regret the absence of one person perhaps more than any
141 Professor Sir Edward Abraham Kt CBE FRS (1913–1999) was largely responsible for the purification of
penicillin and describing its chemical structure, the discovery of the enzyme penicillinase and the isolation of the
antibiotic, cephalosporin-C. He was Professor of Chemical Pathology at the Sir William Dunn School of
Pathology, University of Oxford, from 1964 until his retirement in 1980, when appointed Emeritus. He founded
the Edward Penley Abraham [EPA] Research Fund and the EPA Cephalosporin Fund Lectures with part of his
personal share of the cephalosporin royalties. He was unable to attend the Witness Seminar. See Anon. (1999) Sir
Edward Abraham. The Times (12 May 1999), 21. A video interview with Sir Edward Abraham, conducted by
Professor Richard Thomas, is in the archives of the Biochemical Society.
142 Professor Sir Ro b e rt Robinson Kt FRS (1886–1975), chemist, was Waynflete Professor of Chemistry at the
Un i versity of Oxford from 1930 until his re t i rement in 1955. During the war he became invo l ved in the deve l o p m e n t
of penicillin, publicly supporting one view of its chemical stru c t u re. He was President of the Royal Society from 1945
to 1950 and re c e i ved the Nobel Pr i ze for Chemistry in 1947 for his work on the chemistry of natural products. Se e
Todd A R, Cornforth J W. (1976) Ro b e rt Robinson. Bi o g raphical Memoirs of Fe l l ows of the Royal Society 2 2: 415–527.
143 See biographical note 99 above. 
144 A useful extension can be found in Stewart (1965) op. cit. note 10 above, pages 159–172, 185–191.
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other who should be here today and that is Sir Edward Abraham145 who, with Lord
and Lady Florey, and others, notably Norman Heatley,146 not only confirmed the
microbiological activity of the original penicillins and cephalosporins, several of them,
but also came very near to a complete chemical identification within a period of two
or three years. So we had not only 6-APA in the late 1950s, we also had 7-ACA,
7–aminocephalosporanic acid, the difference being that the penicillin sulphur-
containing ring was five-membered, whereas this was a six-membered dihydrothiazine
ring, but otherwise a lactam structure very similar to the penicillins, similar in
structure, similar in lack of toxicity, similar in action on the muramic acid peptide of
the bacteria cell wall. This was fascinating. I came across it, not because of what we
now use as the therapeutic cephalosporins, but because of cephalosporin-N, which in
fact was a penicillin with a straight side chain with an amino group which foresaw
what Peter Doyle and Ralph Batchelor have already referred to, as the widening effects
of the spectrum of the basic group on the side chain. This brought into focus the
possibility of widening the entire b-lactam spectrum and that has indeed proved to be
the case. This was foreseeable in the mid-1950s before there was a therapeutic
cephalosporin available, but work proceeded and apart from the wonderful chemical
work done by Abraham and Newton,147 it became possible to work out all kinds of
other complex structure–activity relationships and to produce new antibiotics with
better, wider spectra which we depended upon for years. But the first two were very
disappointing. Cephalothin, which was made by Lilly with a thioenyl side chain, was
actually quite disappointing clinically, so an effort was made by Glaxo, who were the
other people in the field with the support (I had the same support myself at that time)
from the National Research Development Corporation, thanks to Dr Bard. This led
to elaboration of the more complex side chain of cephaloridine which was very active
indeed, except that it was highly unstable. The reason was quite simple and emerged
accidentally. It polymerizes and it is also light sensitive, so the only way to make it for
therapeutic use was to grow it under nitrogen in the dark. In patients it was very
effective indeed at the right time, because it had combined action against gram-
positive cocci and gram-negative bacilli, which made it useful in respiratory infections
and in urinary infections, which were becoming an increasing problem as organisms
learned to be resistant to ampicillin.
This went on on both sides of the Atlantic intensively, and the support of the NRDC
in Britain in making cephalosporins available on a semicommercial basis to interested
scientists was, I think, quite unique. They deserve a great deal of belated recognition
145 See biographical note 141 above.
146 Dr Norman Heatley OBE (b. 1911), chemist, who worked with both Chain and Fl o re y, devised a test to determine
the strength of penicillin, the ‘Oxford unit’, also a technique and the equipment in which to grow penicillin. He spent
his working life from 1936, except for secondments or sabbaticals, at the Sir William Dunn School of Pa t h o l o g y,
O x f o rd, and from 1942 as a Senior Re s e a rch Of f i c e r, later Un i versity Lecture r, until his re t i rement in 1978. Se e
Heatley N G. (1990) Penicillin and luck. In Moberg C, Cohn Z A. (eds) Launching the Antibiotic Era: Pe r s o n a l
accounts of the discove ry and use of the first antibiotics. New Yo rk, NY: Rockefeller Un i versity Press, 31–41.
147 Newton G G F, Abraham E P. (1954) Degradation, structure, and some derivatives of cephalosporin-N.
Biochemical Journal 58: 103–111. 
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for what they did. I think we would not have cephalosporins without them, just as we
wouldn’t know anything else without Brotzu, Florey, and Abraham. The clinical trial
started at the medical school of the University of Indiana. Other trials went on in this
country and elsewhere, and very soon found their place. The more complex molecular
structures offered the possibility for alternative substitutes, and a much wider range of
derivatives became available very quickly. We are using many of them still. They keep
outpacing each other. It was like the barbiturates in the 1930s and 1940s, the chemists
learned how to make permutations and very soon there were all kinds of derivatives
with varying usefulness and patents by improvement and what not. Many of these
things had a very short life, and I am sorry to say that this was true of the two original
cephalosporins, cephalothin and cephaloridine, because they were quickly outpaced. 
Other things happened too. It appeared that the allergenicity, which was a problem
with the penicillins, did not apply to the cephalosporins. Nothing was quite so
allergenic as penicillin-G because it was so extremely reactive, in particular when
conjugated with protein. These b -lactams have all kinds of interesting properties
outside the therapeutic field. For example, they make wonderful chemical colours,
and all kinds of things which have been used in other fields. The cephalosporin
molecule appeared able to evade some of the cross-allergenicity. There is some
marginal overlap, probably because of minor determinants in the antigenic process,
but it’s not nearly so bad. Hence cephalosporin came to replace penicillin in highly
allergic subjects, although these problems began to be dealt with by the discovery that
penicillin could in fact be rendered clear and free from the allergenic protein, and
again this was work in which Beecham’s played a very, very large part. The other thing
was the toxicity. Cephalosporins were nephrotoxic148 up to a point but that was
overcome by chemical changes and then the final problem was polymerization which
is an unresearched chapter, because both the b-lactam antibiotics, cephalosporins and
penicillins, are highly liable to polymerization. This is a phenomenon in itself (bio-
polymerization), which played a part naturally in the mode of action in the cell wall
and also in the complication of allergy by providing a base to which proteins became
linked, during manufacture or clinically.
P ro fessor David Gre e n wo o d :149 I am always fascinated by the way that Lady Luck seems
to be hiding in the wings in drug discove ry and I think that cephalosporins are a ve ry good
example of this. After all, Brotzu published his original description in Italian, in a journal
that he is said to have founded for that purpose,1 5 0 and anything more likely to relegate it
148 For a description of the nephrotoxicity of cephalosporins, see Selwyn (1980), op. cit. note 68 above, page 109.
149 Professor David Greenwood (b. 1935) was born in the year that Prontosil, the first sulphonamide, was described.
He has been at the University of Nottingham Medical School since 1974 and Professor of Antimicrobial Science
since 1989. He held a Wellcome Trust History of Medicine Fellowship for Clinicians and Scientists from October
to December 1993.
150 Professor Greenwood wrote: ‘I suspect that the claim may be apocryphal. It is more likely that L a vori dell’ i n s t i t u t o
d’ Igiene di Ca g l i a r i was an occasional publication, which Brotzu used to document his discove ry. The Wo rld List of
Scientific Pe r i o d i c a l s (1964) lists a journal with a ve ry similar title – L a vori dell’instituto d’ Igiene dell’ Un i versità di
Ca g l i a r i with issues from 1940.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999. op. cit. note 138 above .
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to obscurity can hardly be imagined. It was only through a British contact, Blyth
Brooke, a British medical officer who worked in Italy at the end of the war, that the
Cephalosporium mould was brought to England and drawn to the attention of the
Oxford group. Moreover, the antimicrobial activity of the Cephalosporium mould that
Brotzu discovered was not due to a cephalosporin, it was due to a penicillin and a
steroid antibiotic; cephalosporin-C was a very minor component. So I think we
should remember that we owe Lady Luck quite a debt of gratitude in this, as in many
other discoveries. 
Booth: If it was found in the penicillin part, why did people go on looking at the
cephalosporin side of it?
Batchelor: I was just going to say that luck yes, but one has to accept that when Guy
Newton and Edward Abraham found an impurity in their penicillins, they recognized
cephalosporin-C by its unique effect,151 so at least they made an observation again and
did something about it. I think that’s the important thing.
Dr Leo Hepner:152 I wonder if we could have some comments about another feature
which follows on from cephalosporin-C and 7-ACA. Dr Ba rd mentioned
cephalosporanic acid, but in fact there were two cephalosporanic acids: 7-ACA and 
7-ADCA. The latter was developed by Eli Lilly almost as a way of circumventing the
NRDC patent, thereby entering into the cephalosporin business through the back
door. Once this 7-ADCA route was established, half the cephalosporin business was
removed from the orbit of the NRDC. Perhaps we could hear about this?
Bard: I left the NRDC in 1975, and during that time I had no intimation that they
[Eli Lilly] had cephalosporanic acid.
Stewart: Yes, I am wondering what back door is being referred to, because there were
a number of back doors and side doors in this whole industry. It was quite complex.
There’s no doubt that there were several cephalosporins and of course at that time,
since the structure of penicillin itself was in some doubt, the President of the Royal
Society [Sir Robert Robinson153], for example, thought that it was a oxazolone and not
151 Professor Greenwood wrote: ‘Because it was found to be stable to staphylococcal b -lactamase, which was causing
i n c reasing problems in the treatment of staphylococcal infections at the time.’ Letter to Mrs Lois Reynolds, 16
October 1998. Professor Greenwood later wrote: ‘Professor Sir Ed w a rd Abraham has made this clear in print on
s e veral occasions. A suitable re f e rence would be Abraham E P. (1990) Oxford, How a rd Fl o re y, and World War II. In
Moberg C L, Cohn Z A. (eds) Launching the Antibiotic Era . New Yo rk: Rockefeller Un i versity Press, 19–30. See page
29 for the statement about resistance to staphylococcal penicillinase.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999.
152 Dr Leo Hepner (b. 1930) has been a management consultant in fermentation biotechnology since 1970. He
founded the biotechnology journal, Process Biochemistry, in 1965 and has established extensive contacts with
companies and personalities involved in the area of penicillins and cephalosporins. 
153 Clarke H T, Johnson J R, Robinson R. (eds) (1949) The Chemistry of Penicillin. Report on a collaborative
investigation by American and British chemists under the joint sponsorship of the Office of Scientific Research
and Development, Washington DC, and the Medical Research Council, London. Princeton, NJ: Princeton
University Press. op. cit. note 142 above. See also Sheehan J C. (1982), op. cit. note 118 above, pages 92–122. 
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a ring structure at all and that held things up for quite a long while, because people
don’t usually go round contradicting the President of the Royal Society when he is a
chemist. But what became quite clear was the essential antimicrobial activity resided
in the 7-ACA derivatives, that what was cephalosporin-N would now be called
penicillin-N and it’s not really a cephalosporin at all. The essential activity was
different from penicillin and quite distinguishable, and belonged to the 7-ACA
nucleus and its appropriate side chains. But without the side chains it’s like 6-APA,
relatively inert.
L a m b e rt : In the early years in which the first cephalosporins we re introduced I
would have said that there was always an earlier drug – I think David [Gre e n w o o d ]
will back me up on this – which was accessible. Even in those years the problem of
resistance was already ve ry much in the fore f ront of our minds, the effort was
a l ready being made to restrict antibiotic usage. W h e re I worked, mainly at St
Ge o r g e’s Hospital, for many years our drug policy only included one cephalosporin
which was rather rarely used, so I think with re f e rence to the early years, there was
ve ry limited extension of the existing range except for certain specific infections, as
Professor St ew a rt has indicated. I wouldn’t quite agree with him about allergy.
T h e re’s enough cross-allergy to make cephalosporins undesirable where there is
p rofound danger like anaphylaxis or angioedema, but where so often the story of
allergy is an indefinite or vague or mild one, then of course, they made a lot 
of differe n c e .
Scott:154 I started my career in infectious diseases very early on in the 1970s, and oral
cephalosporins were just becoming available then, and I do remember that they were
being used for some patients with Staphylococcus aureus abscesses who were allergic to
penicillins. The general feeling was that they were not particularly effective against
gram-positive infections, and that feeling has continued all the way through until now.
In fact, as new cephalosporins have been developed they have been less and less active
against gram-positive infections, and more active against gram-negatives. The other
point about them, which is interesting to me from a historical point of view, is that
their development and spread was very, very extensive in the United States of America,
whereas the penicillins held sway here and that is something which is really quite
difficult to understand for me. It must be something to do with marketing or the
particular preferences of clinicians or the drug companies and maybe someone here
has got some answers to that. 
Lambert: I did make an attempt to quantify the point that Geoff [Scott] has just made
some years ago by finding from various friends in the industry the tonnage of
injectable cephalosporins used in three countries – the UK, Japan and the United
States of America – and by simple extrapolation of populations I found, if I remember
rightly, that if you counted the tonnage of injectable cephalosporins per patient as one
154 See biographical note 94 above.
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in the UK, it was eight in the US and 13 in Japan, and I think that there is nothing
that I know about epidemiology of infectious diseases which would explain that!155
Bard: The point that I would like to make, Mr Chairman, is very simple: that we had
experience in the UK that, in confirmation of the figures that Dr Lambert has given,
there was a bias against cephalosporins in the UK. But on the other hand, we always
took the view that they were useful in three conditions: where penicillin didn’t work,
where it was inactive, and where penicillin was contraindicated.
Batchelor: There are actually a number of reasons for this sort of thing and it’s
certainly not epidemiology. Let’s take Japan. The answer is actually very simple why
Japan has a very large number of cephalosporins. It’s all to do with the reimbursement
of doctors, who get a percentage of the cost of the product that they prescribe, and
with the way that the Japanese Government works. They reduce prices regularly so
that it’s the latest product that has the highest price and therefore the doctor prescribes
the most recent products, which were developed by Japanese companies, and he gets
the most money, so there’s a very simple situation in Japan. In the United States there
are a number of reasons, it’s undoubtedly partly marketing, it’s partly historical
situations. As an aside, at the moment, semisynthetic penicillins of course, which are
very big in the UK and in the USA, are almost zero in Germany because Germany is
still a sulphonamide market, it still goes back to the pre-war, so it’s quite interesting
there, custom and practice come into it. Apart from the marketing strength of
different companies, and certainly the US had a very high marketing strength.
Beecham was actually relatively weak in the States, Bristol-Myers didn’t do as good a
job as [Eli] Lilly did, that’s one of the reasons. The other reason with some of the
newer injectable products, is that there is also prescription by fear in the United States,
fear of a lawsuit by the doctor having to face a lawyer that’s saying, ‘Doctor, did you
know that this drug was the latest and most efficient, why didn’t you prescribe it to
my patient?’ and that affects what happens in the United States, and I think you will
have to take all of these things into account before you start thinking whether it was
the epidemiology or not.
Eveleigh: I hope this isn’t too frivolous, but just before I left the States to come to this
meeting, I phoned Richard Ellander at Bristol-Myers and he commented that the
current world sales for antibiotics were $22 billion, basically the b-lactams were $12
billion, in other words over half, of which the cephalosporins dominated. 
Batchelor: That’s absolutely right. The actual sales of cephalosporins in dollar terms
are higher than the penicillins, that’s partly because of the higher price, but another
contributory factor is the fact that most of the cephalosporins are injectable, whereas
most of the penicillins, particularly ampicillin and amoxycillin, are mainly oral and
155 Professor Harold Lambert wrote: ‘I made the analysis for a lecture and never published it.’ Letter to Mrs Lois
Reynolds, 27 March 1999.
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the price of injectable products is obviously much higher because the cost of making
a sterile product for injection and packaging in that form is actually much more costly
than making an oral product. So that’s one of the reasons. 156
Ayliffe: There was another difference. When cephalosporins were first manufactured,
cephaloridine was produced in this country and cephalothin was produced in the
USA. Cephaloridine was less stable to b-lactamases than cephalothin and less effective
for treating staphylococcal infections. This may be another reason why cephalosporins
were less frequently used in this country. I wonder if Pamela would like to comment? 
Waterworth: I can’t remember.
G re e n wo o d : T h e re must be a large element of marketing in all this. At one time
cephalexin was the top-selling cephalosporin in the world, a singularly dull and inactive
cephalosporin, the most useful pro p e rty of which is oral absorption. Cephradine, when
it became available, which is identical in any parameter you care to mention, quickly
ove rtook it in the market because the manufacturers brought out a more expensive ,
injectable form of this well-absorbed compound. In It a l y, there is a compound called
p i valexin, which is said to be better absorbed than cephalexin (which is 100 per cent
absorbed). When I looked up the world literature on pivalexin, I discove red that there
was one paper in Italian in which eight patients had been tre a t e d .
Booth: We will now move on to discuss resistance and immunity. I wondered if we
could ask Professor Naomi Datta if she would be so kind as to start us on our way.
P ro fessor Naomi Datta:15 7 Well I will have to move into molecular biology. We’ve
a l ready heard about bacteria mutating to resistance and in the 1950s it was assumed that
that was always the way in which bacteria did it. Then there came the publications fro m
Ja p a n ,1 5 8 stating that multiple resistance, that is to four unrelated drugs – stre p t o m yc i n ,
t e t r a c ycline, chloramphenicol and sulphonamides – could be transferred from one
156 Dr Ralph Batchelor wrote: ‘Actual tonnage of penicillin produced far exceeds the cephalosporin-ampicillin and
a m ox ycillin alone comes to 16 500 tonnes.’ Letter to Mrs Lois Reynolds, 14 October 1998. Dr Batchelor later wro t e :
‘The paragraph ought to end by saying that the tonnage produced and the number of patients treated is, howe ve r,
the re verse. The actual tonnage of penicillin produced in 1995 was around 24 000 for penicillin-G and 9000 for
p e n i c i l l i n - V, of which only c . 4000 tonnes of penicillin-G and 1600 tonnes of penicillin-V we re used directly as
antibiotics in their own right – most of the rest being conve rted to semisynthetic penicillins and cephalosporins. Ove r
6000 tonnes each of ampicillin and amox ycillin we re made together with over 1000 tonnes of other semisynthetic
penicillins. In the same year the total tonnage for all cephalosporins was 4700. The same source gives the US dollar
values as $9.3 billion for cephalosporins and $5 billion for semisynthetic penicillins, agreeing well with Dr Eve l e i g h’s
f i g u re. The re f e rence for my figures is Penicillin and Cephalosporin Business Re p o rt s , Michael Barber and Associates, 18
Croydon Road, Caterham, Su r rey CR3 6QB.’ Letter to Mrs Lois Reynolds, 24 Ma rch 1999.
157 Professor Naomi Datta FRS (b. 1922) was Professor of Microbial Genetics in the Department of Bacteriology,
Royal Postgraduate Medical School, Hammersmith Hospital, London, until her retirement in 1984, now
Emeritus. She had been a member of staff at the Central Public Health Laboratory, Colindale, before moving to
the Hammersmith as Assistant Lecturer in 1957.
158 op. cit. note 6 above.
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bacterium to another. This possibility was suggested by the isolation of bacteria of
d i f f e rent genera, Sh i g e l l a and Es c h e r i c h i a, from clinical material, with the same re s i s t a n c e
pattern. Evidence was sought by growing resistant Sh i g e l l a in mixed culture with
s e n s i t i ve E. coli. From the mixture, resistant E. coli was isolated. This was not thought
to be ve ry likely by the people with whom I was in contact at Hammersmith. By that
time Bill Ha ye s’s MRC Unit on Mi c robial Genetics was set up in the Ha m m e r s m i t h .
Bill, on the assumption that resistance was acquired by mutation, encouraged the use of
multiple antibacterial therapy since that should pre vent the emergence of re s i s t a n c e .15 9
Howe ve r, in 1959 we had an outbreak of Salmonella typhimurium at Ha m m e r s m i t h
Hospital and I collected the many isolates. Afterwards, when we were less busy from
the results of the epidemic, I went through them looking for variations between the
different isolates, and to my great surprise I found that a few were resistant to the three
drugs – streptomycin, tetracycline and chloramphenicol. The Japanese had already
published their findings, which I probably wouldn’t have noticed if it hadn’t been that
Denny [Mitchison] had pointed out the paper to me.160
Booth: He’s very good at pointing out papers to people.
Datta: A very useful function. Anyway, having got these ones, I then tried the test.
Would they transfer their resistance in mixed culture from a Salmonella to an E. coli.
Sure enough they did. This was really exciting for me personally but also it was very
important for molecular biology,161 because the DNA molecules which had been
transferred from one bacterium to another, plasmids as they are called, can be used as
vehicles for, well really any genetic material you like to put into them. That’s the whole
basis of genetic engineering. 
Not only was the finding that the plasmids carrying resistance could be transferred
from one bacterium to another, but quite soon afterwards it appeared that individual
resistance genes could hop from one plasmid to another. We called these transposons.
It turns out that in the DNA of all of us here, there are vast numbers of transposons
in our chromosomes. So altogether these little findings to do with clinical bacteriology
have made a great difference to the understanding of genetics and molecular biology.
Booth: Can I just ask, in terms of resistance clearly these plasmids became important.
Could you see them or extract them? How did you know they were there?
159 Professor William Hayes FRS (1913–1994) joined the Postgraduate Medical School at Hammersmith Hospital,
London, as Senior Lecturer in bacteriology in 1950 and was invited to set up the MRC Microbial Genetics
Research Unit there as director, in 1957. In May 1968, on his appointment to a personal chair at the University
of Edinburgh, the Unit moved to Edinburgh and was renamed the Molecular Genetics Unit. The Unit closed on
Hayes’s departure to the Research School of Biological Sciences at the Australian National University in 1974
where he remained until his retirement in 1979. For a description of the discovery of the transmissible plasmid,
see Broda P, Holloway B. (1996) William Hayes. Biographical Memoirs of Fellows of the Royal Society 42: 171–189.
160 op. cit. note 6 above.




D a t t a : Oh, that was ve ry simple, you just grew the mixed culture on a selective medium
containing the drug, tetracycline, say, to which resistance was being studied. It’s the
DNA that’s transferred from one to the other. Only DNA. Not protein or RNA at all. 
L a m b e rt : I would like to follow Professor Datta directly because the paper which she
published, which I have here, gave me one of those extraord i n a ry and vividly exc i t i n g
moments where fundamental advance in biology links up with one’s clinical practice there
and then. I’d recently gone from UCH to St Ge o r g e’s and we we re beginning to see strains,
mainly of Sh i g e l l a and Sa l m o n e l l a, with multiple resistance to various drugs. I found this
intensely mystifying, because we knew that the actual mechanisms of resistance to say
t e t r a c ycline, sulphonamide, stre p t o m ycin, we re different one from the other. The idea that
they could go as a package was intellectually tormenting me. It didn’t make too much
d i f f e rence to patients getting better, but it worried me a lot. My reading of the Ja p a n e s e
Jo u rnal of Experimental Science 1 6 2 h a d n’t been too fastidious, but I was actually reading the
Jo u rnal of Hy g i e n e religiously and we had here Naomi Da t t a’s transmissible drug re s i s t a n c e
in an epidemic strain of Salmonella typhimurium, the paper which Naomi has just re f e r re d
t o.1 6 3 I thought it was extraordinarily vivid and it really explained what we we re seeing
clinically in the wards. As Naomi has said, things have gone on to identify transposons and
i n t e g rons, and we know a lot more about the way in which bacteria re c ruit resistant genes
and put them into a package which can then act in effect as a virulence factor and be
t r a n s f e r red as a whole. But this was the first actual glimmering that we had. 
If I might just make one other point. Although the molecular biology has gone on a
long way since those years, there is a great deficiency of knowledge about the actual
events in the ecosystems in which these transfers take place. Looking back at this paper
by Naomi I see that she had the prescience to look at a lot of faecal specimens from
stools of patients collected at Hammersmith and found in fact one Shigella sonnei and
three E. coli carrying the same form of multiple resistance. Although this paper is in a
prestigious journal of 1962, not many people have done that sort of thing, and it links
directly with what we were talking about earlier, that the problem of antibiotic usage
is two problems, one of antibiotic use, and the other of control of cross-infection and
this still has a long way to go.
Booth: Professor Datta, could I just come back to you. I remember those days and I
think I remember that epidemic that you studied. Didn’t you call them R factors to
begin with? And what did you think they were at the beginning?
D a t t a : Yes, they we re called R factors for resistance factors. Yes, and because of Bi l l
Ha ye s’s unit, I did know a little about genetics. What was already known before the R
factors, as we called them, we re discove red, was something called the F factor of E. coli,
f e rtility factor, and this fertility factor was able to bring about the transfer of genes 
f rom one strain of E. coli to another. This was the work of Lederberg, and it followe d
162 op. cit. note 6 above.
163 op. cit. note 161 above.
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on the work of Beadle and Tatum on Ne u ro s p o ra about genetic combination in
m i c ro o r g a n i s m s .1 6 4 The F factor was transmissible from one bacterium to another. It
d i d n’t carry anything with it as a general rule, except itself. In fact, I remember when
Bill [Ha yes] used to give lectures about the F factor, he would say, ‘It’s an extraord i n a ry
thing that if you put one male into a large population of female bacteria, by the next
morning they would all be the males’. And so because that was known alre a d y, there
was obviously some connection between the F factor and the R factor. 
Booth: Transfer of material.
Greenwood: This provoked the famous headline ‘Hayes says sex is infectious’.165
Ay l i f fe : Can I give another example of a new plasmid appearing in the late 1960s?
Pseudomonas aeru g i n o s a was one of the most important causes of infection in burns
patients and was resistant to most available antibiotics except polymyxin B and colistin,
which we re both toxic. Carbenicillin was the first penicillin to be produced which was
a c t i ve against Ps e u d o m o n a s and was a major advance. It was then noticed by Ed w a rd
L ow b u ry that Ps e u d o m o n a s strains and other gram-negative bacilli in the unit we re
resistant to carbenicillin and also to kanamycin, which was not used in the unit at the
t i m e .1 6 6 This and other evidence suggested to us that this resistance was probably due
to a new plasmid. Professor Richmond1 6 7 t r a n s f e r red resistance to these two antibiotics,
and also to tetracycline and ampicillin together and rapidly published the results. T h i s
was an important plasmid with an unusual ability to move between species.
Booth: Now can I just get clear in my very thick mind what the plasmid is doing. You
have got a ring of DNA that goes from a bacterium to another one and that carries
the resistance. I assume that the plasmid must code for an enzyme of some sort which
attacks the antibiotic. 
Datta: It carries genes determining proteins. Penicillinase is the most obvious one, but
there are many others. In tetracycline resistance, some protein prevents tetracycline
getting into the cell. In the case of chloramphenicol resistance it’s a chloramphenicol
transacetylase that inactivates the drug. There are a whole lot of different genes with
known functions which are carried on these little molecules.
Booth: Now can that happen in any bacterium, or is it specifically for the four gut
bacteria that you were involved with? 
164 Joshua Lederberg (b. 1925), George Wells Beadle (1903–1989) and Edward Laurie Tatum (1909–1975) shared
the 1958 Nobel Prize for Physiology or Medicine for their description of the role of genes in biochemical processes.
For F factors and R factors see Hayes W. (1968) The Genetics of Bacteria and their Viruses: Studies in basic genetics
and molecular biology. Second edition. Oxford: Blackwell Scientific Publications, 746–808.
165 Professor David Greenwood wrote: ‘I am afraid I can give no reference for this headline, though the story was
circulating in the late 1960s and was, I believe, true.’ Letter to Mrs Lois Reynolds, 24 March 1999.
166 Lowbury E J L, Kidson A, Lilly H A, Ayliffe G A J, Jones R J. (1969) Sensitivity of Pseudomonas aeruginosa to
antibiotics: Emergence of strains highly resistant to carbenicillin. Lancet ii: 448–452.
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Datta: Oh no, staphylococci and streptococci have them too and they are also
transmissible.
M i t c h i s o n : The one important pathogen in which plasmids don’t exist is
Mycobacterium tuberc u l o s i s and that I think is because M. tuberc u l o s i s d o e s n’t come into
contact with other bacteria and so doesn’t gain any additional va r i a b i l i t y, which is what
the plasmids are really doing. The other important consequence is that combined
t reatment works with tuberculosis, because you don’t get transmission of multiple
resistances, but it works much less effectively when you have plasmid transfection. 
The other point I think I should make is because Naomi mentioned transposons.
Transposons are the basis of the very good epidemiological classification of different
strains of tubercle bacilli. It’s where the many copies of the plasmid actually lodge in
the tubercle bacillus genome that determines the many million possible combinations
of different patterns that you get which remain constant for individual strains. 
B o o t h : What about manufacturers of antibiotics? To what extent was your policy in
pursuing newer antibiotics from year to year induced by knowing what was going 
on about resistance? Did it matter to the way in which you approached 
your pro g r a m m e ?
Cole: Well, the answer to that I think is that it definitely had a major influence on us,
but I don’t know whether you want to at this point open up the whole subject of b-
lactamase inhibitors. Once it became well appreciated and understood that
destruction of penicillins by penicillinase was a major resistance mechanism, of course
we in the industry were very keen to try and find ways round it. One way, as has been
mentioned already, was by selecting molecular structures that had intrinsic stability to
these enzymes built in, as in methicillin and isoxazolyl penicillins. But that approach,
of course, didn’t really apply to the gram-negative bacteria; it was very difficult there
to achieve in-built stability to their destructive enzymes. Bearing in mind that
penicillinases occurred very widely, and were of all sorts of different types, later to be
called b-lactamases, because of their great variety, and the fact that some attacked the
cephalosporins as well, this led to the thought that maybe one could have an approach
of using an additional substance to inhibit the enzyme. As Edward Abraham’s name
has been mentioned already, I thought I would just read to you one little snippet here,
a rather profound thought that he had which he published in 1972. He said, ‘The
irreversible inactivation of a b-lactamase by an appropriate substrate, though mor e
promising in principle than competitive inhibition as a method of mitigating the
contribution of these enzymes to bacterial resistance, is at present more remote from
167 Sir Ma rk Richmond Kt FRC Path FRS (b. 1931) has been a member of the School of Public Policy at Un i ve r s i t y
College London since 1996. He was Group Head of Re s e a rch of Gl a xo Holdings from 1993 to 1995. From 1990 to
1994, he was Chairman of the Science and Engineering Re s e a rch Council, having been Professor of Bacteriology at the
Un i versity of Bristol from 1968 to 1981, and Vice-Chancellor and Professor of Molecular Mi c robiology at the Un i ve r s i t y
of Manchester from 1981 to 1990. He was unable to attend the Witness Se m i n a r. See Sykes R B, Richmond M H.
(1970) Intergeneric transfer of a b-lactamase gene between Pseudomonas aeru g i n o s a and E. coli. Na t u re 2 2 6: 952–954.
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practical application’.168 What he was getting at was there were some examples where
one compound could act as a competitive inhibitor and protect another, but he was
thinking that what would be nicer would be if the inhibitor actually inactivated the
enzyme, but that really wasn’t known at that time. 
I think he was the first to observe that cephalosporin-C was actually a b- l a c t a m a s e
i n h i b i t o r. That was in 1956, and a few years later George Rolinson and Ralph Ba t c h e l o r
found that methicillin actually acted as an inhibitor also.1 6 9 And of course having
d i s c ove red methicillin, it was natural to then look at the isox a zolyl penicillins and some
of those we re really ve ry good, like cloxacillin. Cloxacillin was ve ry extensive l y
i n vestigated in combination with ampicillin; the combination Am p i c l ox [ampicillin with
c l oxacillin: Beecham], was quite good against some resistant bacteria, but the effect re a l l y
w a s n’t extensive enough to make big claims for enhancing the activity of ampicillin.
So there was still a big need for a better compound and in our labs, at Brockham Pa rk ,
we thought that as it’s well established that certain b-lactam compounds can act as
inhibitors, maybe we could screen all the penicillins we had made. Well we had made
an awful lot of compounds and by the time that I started looking at them, we had in
the cupboards over a thousand semisynthetic penicillins. It was not going to be easy to
do biochemical tests on that number of compounds, so we devised an automated
p ro c e d u re. Some of you may remember the Technicon equipment where fluid
separated by bubbles of air was pumped along tubes; we adapted that methodology and
s c reened all these compounds. We did in fact find some that we re a big improve m e n t ,
and one we published on, BRL 1437, we had high hopes for.1 7 0 The only trouble was
that if you wanted to put it together with something like ampicillin or amox ycillin it
w a s n’t going to be much good. In one of those ve ry quick volunteer studies, I think I
s w a l l owed a small amount of it, we discove red that the oral absorption was terrible. So
we really didn’t make much pro g ress on trying to find an inhibitor from the existing
semisynthetic penicillins or even the cephalosporins, although the Gl a xo people had a
look too and they found one or two of their cephalosporins we re quite good inhibitors. 
At about the same time we started screening microorganisms to see if they produced
b-lactamase inhibitors, after all, cephalosporin-C was a microbial metabolite that had
been shown to be an inhibitor, so there was some precedent for microorganisms
producing b-lactamase inhibitors. We mounted a substantial screen, using not an
168 Abraham E P. (1972) Biosynthesis and Enzymic Hydrolysis of Penicillins and Cephalosporins. Tokyo: University of
Tokyo Press, 74.
169 Rolinson G N, Stevens S, Batchelor F R, Cameron-Wood J, Chain E B. (1960) Bacteriological studies on a new
penicillin – BRL 1241. Lancet ii: 564-567. op. cit. note 113 above. See also Abraham E P, Newton G G F. (1956)
A comparison of the action of penicillinase on benzylpenicillin and cephalosporin-N and the competitive
inhibition of penicillinase by cephalosporin-C. Biochemical Journal 63: 628–634.
170 Cole M, Elson S, Fullbrook P D. (1972) Inhibition of the b-lactamases of Escherichia coli and Klebsiella aerogenes
by semisynthetic penicillins. Biochemical Journal 127: 295–308. Professor David Greenwood wrote: ‘BRL 1437
(2-isopropoxy-1-naphthylpenicillin) was first described by Martin Cole and his colleagues in 1972. Professor
Francis O’Grady and I investigated the activity of this compound in vitro.’ Letter to Mrs Lois Reynolds, 24 March
1999. See Greenwood D, O’Grady F. (1975) Potent combinations of b-lactam antibiotics using the b-lactamase
inhibition principle. Chemotherapy 21: 330–341.
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automated biochemical method in that case, but a simple antibacterial synergy test
using Klebsiella pneumoniae which was resistant to penicillin-G. If you put in
something like methicillin, the methicillin would stop the destruction of the
penicillin-G, and now the organism became sensitive to the penicillin-G. This method
was devised by Dr Rolinson and we adapted it to the screening of large numbers of
organisms.171 We came up with a Streptomyces that produced several extremely potent
b-lactamase inhibitors. Later this class of compounds was to be called the olivanic
acids. The substances were produced in very small amounts, they were very unstable,
and an awful job to isolate. We started to get some information about the properties
of these compounds, and there was a hint that they might be b-lactams, because there
was a competitive inhibition element in the inhibition of the penicillinases, but we
could never isolate enough to do the structural chemistry at that stage. 
Then there was an interesting debate that Peter Doyle here may well remember at a
meeting we both we re at. The cephamycins, the 7-methox ycephalosporins and re l a t e d
compounds, we re described by Eli Lilly and by Me rck. They didn’t mention anything
about b -lactamase inhibition by these compounds, but they we re novel b -lactam stru c t u re s
and so I remember Peter Doyle saying one day, ‘T h a t’s what yo u’ve got, yo u’ve got one of
these cephamycins in your St re p t o m yc e s c u l t u re fluid.’ Our response to that was not to
attempt to get the compounds, which was rather fortunate, but we ord e red the culture that
p roduced the substances. Now Eli Lilly had deposited the culture, it was named
St re p t o m yces clavuligeru s in the American Type Cu l t u re Collection, so you could buy it.
I think it was $30 at the time. We purchased the culture and grew it up, with the idea to
make these new methoxy-cephalosporins. When we carried out the chromatography on
the culture fluid, we found a b - l a c t a m a s e - i n h i b i t o ry substance that wasn’t a cephamyc i n
nor was it an olivanic acid. What we had found we later called clavulanic acid. So that’s
h ow we discove red clavulanic acid and that, of course, was found to be a ve ry good
inhibitor of a lot of the penicillinases, but wasn’t much good against the cephalosporinases.
Datta: Of course it’s important about the penicillinase inhibitor, but then you have to
find inhibitors for all the other different proteins that use different resistances. But, of
course, penicillinase is a very important one.
Doyle: Talking about luck, and Martin [Cole] has mentioned the luck of picking up
that culture, but the other very fortunate thing for us was with clavulanic acid. We
wanted to combine it with ampicillin or amoxycillin and it was going to depend on
the oral absorption. But first of all it was orally well absorbed and if you looked at the
pattern of absorption, it was almost identical with ampicillin. So in vivo we had the
material [clavulanic acid] there when the ampicillin was also there and that was
another stroke of fortune. We knew nothing about that when we started.
171 Dr George Rolinson wrote: ‘Screening of microorganisms for b-lactamase inhibitors was a programme I initiated
myself and I devised the test Dr Cole refers to for the express purpose of doing this work. For the first six months
of the programme I carried out the laboratory work myself, single-handed, and I then increased the scale of the work
by involving other members of the department and this programme resulted in the discove ry of the b - l a c t a m a s e
inhibitors Dr Cole refers to.’ Letter to Mrs Lois Reynolds, 8 June 1999. op. cit. note 101 above, page 599.
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Mitchison: One of the organisms that produces a potent penicillinase is of course the
tubercle bacillus. Now in these days when we have quite a number of multiple drug
resistant strains, it would be extremely useful to have a penicillin which worked on
these resistant strains. I have been trying to get SmithKline Beecham to do the
necessary study of early bactericidal activity, for which the expertise is known, to prove
this point. So what one has to say is that here are the chemists doing some very, very
useful skilled jobs and the developers at Beecham’s failing drastically.
Stewart: All is not lost, Professor Mitchison. There are some things that were left on
the shelf or were somehow lost or forgotten. For example, quinacillin, which is a
semisynthetic penicillin with a quinoline side chain and unusual activity against
tubercle bacilli, as well as being resistant to penicillinase and active against some
strains of methicillin-resistant Staphylococcus aureus (MRSA). Then there are steroid
antibiotics, which include cephalosporin-P1 and the fusidic acid group, also active
against some Mycobacteria. The crude cephalosporins, as found by Brotzu and purified
by Abraham and his colleagues, therefore had a relatively wide spectrum of activity.
There are escape routes for exploration among these rejects, but most of them are
p robably unsuitable for patenting, because like cephalosporin-N and penicillin-T,
they had been messed up by people like me beforehand. They might be of intere s t
o t h e rwise because MRSA, or should I say EMRSA, has a potential for epidemic
s p read in the community as well as in hospitals, and for causing septicaemias with
s e ve re lesions like endocarditis and osteomyelitis. Recent work, mainly in New Yo rk ,
but also in Japan, has identified m e c A genes in strains of EMRSA, which are
p re valent, inva s i ve and come from external sources. Fingerprints of the DNA in these
strains, according to Ro b e rts in the New Yo rk Hospital, show similarity to ‘A rc h a i c
s t r a i n s’ in their word s .172  These strains may there f o re relate to those which some of
us played with in the 1960s, and placed on file with the National Collection of Ty p e
Cu l t u res. This is history which may be of re l e vance to what is going to happen next.
Ay l i f fe : We seem to be discussing staphylococcal resistance again and perhaps at this stage we
should say something about the emergence of MRSA and its subsequent pro g ress. 
As eve ryone is aware, the first methicillin-resistant strain of Staphylococcus aure us was found
by Patricia Je vons at Colindale in 1960,1 7 3 soon after methicillin was introduced clinically.
Many more strains we re isolated in different countries, such as De n m a rk, Sw i t ze r l a n d ,
Australia, India, over the next few years. At that time Professor Borowski from Poland, and
Professor Ång from Tu rkey we re working with Ma ry Barber on MRSA at Ha m m e r s m i t h
Hospital. On returning to their re s p e c t i ve countries, both isolated methicillin-re s i s t a n t
strains before methicillin was available for clinical use. Me t h i c i l l i n - resistant strains spre a d
to many hospitals in this country and we re often associated with resistance to tetracyc l i n e ,
e ry t h ro m ycin and novobiocin, although these we re rarely used for the treatment of
172 Roberts R B, de Lencastre A, Eisner W, Severina E P, Shopsin B, Kreiswirth B N, Tomasz A. (1998) Molecular
epidemiology of methicillin-resistant Staphylococcus aureus in 12 New York hospitals. Journal of Infectious Diseases
178: 164–171.
173 Je vons M P. (1960) ‘Celbenin’ - resistant staphylococci. British Medical Jo u rn a l i: 124–125. op. cit. note 113 above .
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staphylococcal infections after the introduction of penicillinase-resistant penicillins.
There was no evidence that these were linked on a single plasmid. In the late 1960s
and 1970s, MRSA started to disappear from this country, from Denmark, and
Australia and several other countries. The reason for this disappearance remained
uncertain. It was thought that the discontinuation in use of tetracycline and possibly
streptomycin for acute infections might be a possible reason. When we thought the
problem of MRSA was over, new strains emerged again in Australia, the USA, Eire
and, in the 1980s in Britain and many other countries. The reason remains unknown.
Now they are present in most countries of the world and we are unable to eradicate
them, although Scandinavia remains relatively free.
Booth: What do clinicians do if they get a MRSA in their wards?
Lambert: People do sometimes say that in certain problems of resistance we are
already up against the buffers, and in MRSA it’s not very far from that, because the
accepted reserve drug is vancomycin. Such is the resistance problem that people now
talk as if vancomycin is a satisfactory, easy, good drug. In fact, as you well know, Chris
[Booth], it’s a toxic, difficult, pain in the neck to use and in the last few months, well
maybe in the last year, both in Japan and in the States, some vancomycin-resistant
strains have been reported. There are some new agents coming along which do have
activity, but we are almost on the edge of untreatability.
Greenwood: May I just add something to that, because it’s often said that
vancomycin is the last line of defence against MRSA. Strains of MRSA that are
sensitive only to vancomycin (and other glycopeptides) are, in fact, extremely rare.
Most strains are sensitive to other agents, including fusidic acid and rifampicin, two
e xcellent antistaphylococcal antibiotics. Some are sensitive to aminoglyc o s i d e s ,
macrolides or other agents. Doctors who were practising before antibacterial agents
became available – effectively, in the year I was born [1935] – or even in the early days
of penicillin, would be astounded by the amount of choice now on offer. Claims that
we are now approaching the ‘postantibiotic era’ need to be seen in this perspective.
Booth: If these resistances exist in countries that haven’t used these antibiotics, what
price the idea that we are constantly being bombarded with, that resistance is the
result of misuse of antibiotics, either in human disease or in veterinary animals. What’s
the answer to that?
Batchelor: There’s just a couple of points I would make. First of all, I think one has
to recognize that resistance is the price one pays for having an antibiotic and using it
and it shouldn’t be at all surprising, because nature abhors a vacuum and is bound to
fill up that vacuum if you do something about it. But it always worries me when one
talks about misuse of antibiotics, although it’s always that the doctor is accused of
misusing it and I think the doctor has one job only, and that is of treating the patient
sitting in front of him, that’s what his real priority has to be. He can’t be thinking
about posterity. One talks about veterinary usage. To my knowledge, the usage of
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these drugs is much lower than is talked about.174 What one needs to look at
sometimes is at a few other places and I give you one example that I know well. A lot
of people from the Green side think that making ethanol from sugar cane is a very
good, green, sustainable energy source. What I can tell you is that some professors in
Rio were looking at the microorganisms in part of Brazil, and wondered why they
found multiple-resistant organisms. The answer was very simple. The people with
these open-top fermenters, making alcohol from sugar cane, were actually keeping
some of the bacteria away by adding multiple doses of mixed antibiotics like penicillin
and streptomycin. So it wasn’t surprising that the environment was absolutely filled
up with multiple-resistant organisms. So I think we have to look at areas outside
medicine for some of the problems.
Ayliffe: I think I have said before that resistance has emerged to almost every antibiotic
introduced. On discontinuing the use of an antibiotic, resistance usually, but not
always, decreases. One of the problems with methicillin resistance is that it is not
necessarily related to the use of a particular antibiotic. Cephalosporins are possible
selecting agents, but discontinuing their use may be difficult in practice.
Plasmids controlling the resistance to several linked antibiotics also means that
discontinuing the use of one of them might not reduce resistance to that agent if the
others continue to be used. As already mentioned, we should perhaps rely more on the
prevention of cross-infection, and increasing the availability of isolation facilities 
in hospitals.
Booth: Let me just take that point to Professor Datta. Suppose you have a culture of
a group of organisms that have a named or chosen plasmid, whatever you might call
it. If you just watch that culture in successive cell cultures over time, does a plasmid
ever disappear spontaneously, or is it there forever?
Datta: It sometimes disappears spontaneously, but they vary very much on how stable
they are in these conditions.
Booth: And the molecular biologists who use plasmids for genetic engineering,
presumably are choosing specifically stable ones, are they?
Datta: Yes, and smaller ones are usually more stable than big ones. 
M i t c h i s o n : I think there is a specific point about the TB situation and that is that
t h e re is a reasonably good evidence now that if you are taking multiple drugs, as yo u
tend to do in the treatment of TB, and you stop taking them for a bit, and then start
again, and stop, and start, you get the emergence of drug resistance, often to all of
the drugs being used, more or less simultaneously. It’s a slightly unusual
174 Dr Batchelor wrote: ‘In 1995 only 2 per cent of all penicillin-G and -V produced was used in animal feed.’
Letter to Mrs Lois Reynolds, 14 October 1998.
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m e c h a n i s m1 7 5 and I won’t go into that, but I think that certainly exists as a
mechanism. And the second thing is that these multiple-resistant strains do tend to
disappear in the community if you try and get more regular drug treatments. This has
been shown to some extent in America where they had a great many of these in the
big cities, and particularly in New York, and they put a tremendous amount of money
into what they call an outreach programme of actually supervising all the doses of
drugs, and I believe they have achieved substantial reduction in drug resistance. It is
also shown in places like Hong Kong where they supervise all the drug taking, that
they have very little multiple drug-resistant (MDR) tuberculosis. There are however
one or two strains that get about in the community that seem to have perhaps
exceptionally high virulence, and maybe they are exceptions to this rule that you can
get rid of the drug-resistant strains. 
Crofton: The WHO has recently done a world survey of countries with drug
resistance and correlated it with the TB control in that country, and where there’s
good TB control you get very much less drug resistance. As Denny [Mitchison] says,
it tends to disappear and you are not creating new drug resistance if you are giving
group treatment. The other thing that they have shown is that where there is a large
number of re-treatment patients, you get more drug resistance.
Hepner: No-one has yet mentioned the problem of the likelihood that drug resistance
can be transferred from animals to humans. This has been an ongoing problem in
animal husbandry since the late 1960s and early 1970s. In this country the Swann
Committee, chaired by Michael Swann, was established to advise about this issue.
This resulted in the decision by the UK Government to prohibit the use of dosing
low-level antibiotics into animal feed, a custom prevalent all over the world. The
Swann Committee Report was only accepted by the European Community after the
UK’s entry into the European Community.176 The USA has not accepted the Swann
Committee findings, because the FDA has never been able to demonstrate that
resistance is transferred from animals to humans. To this day, nobody knows whether
this is so. It remains an open question.
Lambert: On that last point, I agree with Dr Hepner that rigorous proof is very hard
to come by. There are certain examples which I would particularly mention,
Salmonellas and trimethoprim, and Salmonellas and fluoroquinolines, ciprofloxacin, in
which the epidemiological and temporal evidence is extremely persuasive. I think
175 Mitchison D A. (1998) How drug resistence emerges as a result of poor compliance during short course
chemotherapy for tuberculosis. Internatinal Journal of  Tuberculosis and Lung Disease 2: 10–15.
176 Agricultural Research Council and Medical Research Council, Joint Committee on Antibiotics in Animal
Feeding. (1969) Report on the Use of Antibiotics in Animal Husbandry and Veterinary Medicine. Cmnd. 4190.
London: HMSO. The Committee was chaired by Professor Sir Michael Swann FRS (Lord Swann from 1981)
(1920–1990), of Edinburgh University. The UK entered the European Economic Community along with Ireland
and Denmark in 1973, endorsed by a referendum conducted by the Labour Government in 1975. See Mitchison
J M. (1991) Michael Meredith Swann, Baron Swann of Coln Denys. Biographical Memoirs of Fellows of the Royal
Society 37: 446–460. See also Datta N. (1969) Penicillin in poultry feed. British Medical Journal iv: 741.
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where people get a bit confused is thinking it’s a general problem of human pathogens.
It’s in fact a problem restricted mainly to certain genera, Salmonella, Campylobacter,
enterococci, some E. coli and one or two others. It’s a specific rather than a 
general problem.
Booth: Well, I think we’ve had a very good discussion. We could go on and discuss
parasites and malarial resistance as well if we wanted, but I think that’s a subject on its
own. I would like just to quote from a letter that Tilli Tansey received from Edward
Lowbury, who very sadly can’t be with us here today. He writes, 
‘In the battle of human wits against bacterial genes, the bacteria are seen to have
the advantage of unvarying obedience to their genetic codes, while sadly our
codes of practice are fallible and easily disregarded.’177
And I suppose that is true. But I would like to thank everyone who has contributed
to these discussions this afternoon.
177 Letter from E J L Lowbury to Dr Tilli Tansey, 14 April 1998. op. cit. note 132 above.
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7 - ACA, s e e 7-aminocephalosporanic acid
7-ADCA s e e 7- a m i n o d e a c e t ox ycephalosporanic acid
actinomycetes, 6, 7–8, 9–10
actinomycin, 6, 9
acylase, penicillin, 30, 35
allergic reactions, 42, 44
American Type Culture Collection, 52
7-aminocephalosporanic acid (7-ACA), 41, 43–44
7- a m i n o d e a c e t ox ycephalosporanic acid (7-ADCA), 43
aminoglycosides, 23, 24, 54
6-aminopencillanic acid (6-APA, 





synthesis, 28–29, 30, 32–33, 34, 35
amoxycillin, 28, 31, 36, 46, 63
ampicillin, 28, 31, 33, 35–36, 63
clavulanic acid and, 52
combined with cloxacillin, 51
global use, 46
resistance, 49
Ampiclox (ampicillin with cloxacillin), 51
animal feed, antibiotics in, 55, 56




antituberculous drugs, see also isoniazid; 
para-aminosalicylic acid; rifampicin; 
streptomycin; tuberculosis
clinical use of new, 23–25
multiple resistance, 55–56
antiviral agents, 33–34







BAL, see British anti-Lewisite
Bayer Group, 28–29, 30, 34
Beecham Pharmaceuticals, 5, 25–31, 32–35, 42, 45
Beecham Research Laboratories, Brockham Park, 
Betchworth, 23, 25–29, 51
Bencard, 31
benzyl penicillin, see penicillin-G
b-lactamases (formerly penicillinases)
cephalosporin resistance to, 40, 43, 51
drug resistance due to, 30–31, 50
gene transfer, 49
inhibitors, 31, 50–57
penicillins resistant to, 5, 28, 30–31, 51
in sterility testing, 17
b -lactams, 23, 41, 42, 52, 
see also cephalosporins; penicillin
Brazil, 55
Bristol Laboratories, 28, 32
Bristol-Myers, 30–31, 45
British anti-Lewisite (BAL), 26
British Medical Journal, 23, 31
BRL 1241, see methicillin
BRL 1437 (2-isopropoxy-1-naphthylpenicillin), 51
broad-spectrum antibiotics, 5, 36
Brockham Park, see Beecham Research Laboratories
Brompton Hospital, London, 10–11
Broxil, see phenethicillin






Central Public Health Laboratory, Colindale, 53
cephalexin, 46
cephaloridine, 41, 42, 46
cephalosporanic acid, 40
cephalosporin-C, 39, 43, 51, 59
cephalosporin-N, 39, 41, 44, 59
cephalosporin-P, 39, 53, 59
cephalosporins, 3, 5, 39–46, 53
b -lactamase inhibition, 40, 43, 51
discovery, 59
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chlortetracycline (Aureomycin), 5, 59
Ciba Foundation Symposium, 32
ciprofloxacin, 56–57
clavulanic acid, 52
clinical practice, 36, 38
cloxacillin (Orbenin), 31, 51, 63
cold, common, 13, 16, 60, 61
collapse therapy, 11, 24
Committee on Chemotherapeutics 
and Other Agents, 21–22
Committee on Safety of Drugs, 31, 32
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diethyl disulphide derivatives, 26
dihydrostreptomycin, 17
dimercaprol, see British anti-Lewisite
discontinuation, of antibiotics, 54, 55
DNA transfer, 47–50
dosages, antibiotic, 36, 38
Dubos media, 14–15
Dunlop Committee, see Committee 
on Safety of Drugs
Edinburgh, 14, 15, 24
Edinburgh University, 10, 14, 47
eighth cranial nerve damage, 16–17
Elford membranes, 17
Eli Lilly & Co. Ltd, 45, 52
cephalosporins, 39–40, 41, 43
semisynthetic penicillins, 28, 29
EMRSA, see MRSA
endocarditis, bacterial, 22–23, 37, 53
enterococci, 22–23, 24, 57
erythromycin, 37, 53–54, 59
Escherichia coli, 34, 35, 47, 48–49, 57
ethanol, from sugar cane, 55
ethylmercaptan derivatives, 26
F (fertility) factor, 48–49
factor VI, 30
Federal Trade Commission, 32
fluoroquinolones, 56–57
framycetin, 59
fungi, antiviral agents, 33–34
fusidic acid, 53, 54
gene transfer, 47, 48–50
genetic engineering, 47, 55
Germany, 19, 21, 30, 34, 45
Glasgow, 14, 19
Glaxo Laboratories Ltd, 39, 40, 41, 50





Haemophilus influenzae, 18, 21
Hammersmith Hospital, London, 36–37, 47, 53, 




House of Lords, Select Committee on 
Science and Technology, 3, 38
ICI Pharmaceuticals, 3–4, 26
immobilized enzyme technology, 35
Imperial College, London, 29, 38–39




isoniazid (INAH), 20–21, 24–25, 60–61
2-isopropoxy-1-naphthylpenicillin, see BRL 1437
isoxazole penicillins, 28, 31, 50, 51
Italy, 42–43, 46
Japan
antibiotic resistance, 4, 47, 53, 54
cephalosporins, 40, 44–45
Japanese Journal of Experimental Science, 48
Journal of Hygiene, 48
kanamycin, 49, 59
Klebsiella pneumoniae, 52
lactamases, see b -lactamases
Lancet, 16
Lederle Laboratories, 5, 8
luck, 11–12, 42–43, 52
macrolides, 54
marketing, 31–32, 36, 46
mecA genes, 53
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